Arno Therapeutics 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 21, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'ARNI	'	'
Entity Common Stock, Shares Outstanding	'	20,370,331	'
Entity Registrant Name	'Arno Therapeutics, Inc	'	'
Entity Central Index Key	'0001195116	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$13,810,160

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$26,774,203	$10,943,437
Prepaid expenses and other current assets	86,266	203,516
Total current assets	26,860,469	11,146,953
Property and equipment, net	11,720	24,837
Deferred financing fees, net	0	1,709,530
Security deposit	10,455	10,455
Total assets	26,882,644	12,891,775
Current liabilities	'	'
Accounts payable	2,941,998	1,553,154
Accrued expenses and other current liabilities	925,255	1,652,159
Due to related party	26,039	28,268
Deferred rent	7,797	12,711
Total current liabilities	3,901,089	3,246,292
Convertible debentures, net	0	491,039
Derivative liabilities	35,864,881	21,420,276
Total liabilities	39,765,970	25,157,607
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' (DEFICIT) EQUITY	'	'
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 20,370,331 and 4,545,618 shares issued and outstanding	5,465	3,611
Additional paid-in capital	76,668,966	37,631,339
Deficit accumulated during the development stage	-89,557,757	-49,900,782
Total stockholders' (deficit) equity	-12,883,326	-12,265,832
Total liabilities and stockholders' (deficit) equity	$26,882,644	$12,891,775

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,370,331	4,545,618
Common stock, shares outstanding	20,370,331	4,545,618

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Operating expenses:	'	'	'
Research and development	$13,476,369	$8,537,130	$50,321,577
General and administrative	3,464,180	2,298,671	12,806,792
Total operating expenses	16,940,549	10,835,801	63,128,369
Loss from operations	-16,940,549	-10,835,801	-63,128,369
Other (expense) income:	'	'	'
Interest income	17,737	7,849	431,857
Interest expense	-18,569,157	-6,361,029	-26,190,285
Other (expense) income	-4,165,006	2,801,199	-670,960
Total other (expense) income	-22,716,426	-3,551,981	-26,429,388
Net loss	($39,656,975)	($14,387,782)	($89,557,757)
Net loss per share - basic and diluted	($5.28)	($3.17)	'
Weighted-average shares outstanding -basic and diluted	7,516,223	4,540,321	'

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY (USD $)	12 Months Ended								101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2013
Issuance of common shares	$22,277,098	'	'	'	'	'	'	'	'
Stock based compensation for services	1,456,776	722,811	707,284	249,286	647,448	1,131,218	88,300	9,700	'
Issuance of common shares pursuant to placement agent agreement	'	43,500	'	'	'	'	'	'	'
Warrants issued for services	'	'	'	'	'	480,400	'	'	'
Note discount arising from note conversion	'	'	'	'	'	475,391	'	'	'
Warrants issued in connection with convertible preferred units issued in private placement	'	'	'	-3,340,421	'	'	'	'	'
Warrants issued in connection with note conversion	'	'	'	'	'	348,000	'	'	'
Reverse merger transaction - elimination of accumulated deficit	'	'	'	'	'	-120,648	'	'	'
Reverse merger transaction -previously issued Laurier common stock	'	'	'	'	'	120,648	'	'	'
Warrants issues to placement agents in connection with private placement	'	'	'	464,720	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	0	'	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock	'	'	0	'	'	'	'	'	'
Grant of restricted shares	'	'	115,168	'	'	'	'	'	'
Stock option exercise (in shares)	0	'	'	'	'	'	'	'	'
Stock option exercise	'	'	6,480	'	2,600	'	'	'	'
Issuance of common shares in lieu of liquidated damages	913,510	'	'	'	'	'	'	'	'
Net loss	-39,656,975	-14,387,782	-7,909,113	-4,023,026	-6,936,705	-12,913,566	-3,359,697	-370,893	-89,557,757
Ending Balance	-12,883,326	-12,265,832	1,355,639	8,435,820	1,575,751	7,862,408	-3,627,590	-356,193	-12,883,326
Series C Warrant	'	'	'	'	'	'	'	'	'
Warrants issued for services	5,233,844	'	'	'	'	'	'	'	'
Founders	'	'	'	'	'	'	'	'	'
Issuance of common shares	'	'	'	'	'	'	'	5,000	'
Private Placement	'	'	'	'	'	'	'	'	'
Issuance of common shares	9,158,253	'	'	'	'	17,690,037	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770	'	'	'	13,509,510	'	'	'	'	'
Notes Payable	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	'	'	'	4,278,518	'	'	'
PREFERRED STOCK	'	'	'	'	'	'	'	'	'
Issuance of common shares (in share)	0	'	'	'	'	'	'	'	'
Issuance of common shares	0	'	'	'	'	'	'	'	'
Stock based compensation for services	0	0	0	0	0	0	0	0	'
Issuance of common shares pursuant to placement agent agreement (in shares)	'	0	'	'	'	'	'	'	'
Issuance of common shares pursuant to placement agent agreement	'	0	'	'	'	'	'	'	'
Warrants issued for services	'	'	'	'	'	0	'	'	'
Note discount arising from note conversion	'	'	'	'	'	0	'	'	'
Warrants issued in connection with convertible preferred units issued in private placement	'	'	'	0	'	'	'	'	'
Warrants issued in connection with note conversion	'	'	'	'	'	0	'	'	'
Reverse merger transaction - elimination of accumulated deficit	'	'	'	'	'	0	'	'	'
Reverse merger transaction -previously issued Laurier common stock (in shares)	'	'	'	'	'	0	'	'	'
Reverse merger transaction -previously issued Laurier common stock	'	'	'	'	'	0	'	'	'
Warrants issues to placement agents in connection with private placement	'	'	'	0	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock (in shares)	'	'	0	'	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock	'	'	0	'	'	'	'	'	'
Grant of restricted shares (in shares)	'	'	0	'	'	'	'	'	'
Grant of restricted shares	'	'	0	'	'	'	'	'	'
Stock option exercise (in shares)	'	'	0	'	0	'	'	'	'
Stock option exercise	'	'	0	'	0	'	'	'	'
Issuance of common shares in lieu of liquidated damages (in shares)	0	'	'	'	'	'	'	'	'
Issuance of common shares in lieu of liquidated damages	0	'	'	'	'	'	'	'	'
Net loss	0	0	0	0	'	'	0	0	'
Ending Balance (in shares)	0	0	0	1,909,250	0	0	0	0	0
Ending Balance	0	0	0	1,527	0	0	0	0	0
PREFERRED STOCK | Series C Warrant	'	'	'	'	'	'	'	'	'
Warrants issued for services	0	'	'	'	'	'	'	'	'
PREFERRED STOCK | Founders	'	'	'	'	'	'	'	'	'
Issuance of common shares (in share)	'	'	'	'	'	'	'	0	'
Issuance of common shares	'	'	'	'	'	'	'	0	'
PREFERRED STOCK | Private Placement	'	'	'	'	'	'	'	'	'
Issuance of common shares (in share)	0	'	'	'	'	0	'	'	'
Issuance of common shares	0	'	'	'	'	0	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770 (in share)	'	'	'	1,909,250	'	'	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770	'	'	'	1,527	'	'	'	'	'
PREFERRED STOCK | Notes Payable	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement (in share)	'	'	'	'	'	0	'	'	'
Conversion of notes payable upon closing of private placement	'	'	'	'	'	0	'	'	'
PREFERRED STOCK | PREFERRED	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement (in share)	'	'	-1,909,250	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	-1,527	'	'	'	'	'	'
COMMON STOCK	'	'	'	'	'	'	'	'	'
Issuance of common shares (in share)	7,030,753	'	'	'	'	'	'	'	'
Issuance of common shares	708	'	'	'	'	'	'	'	'
Stock based compensation for services	0	0	0	0	0	0	0	0	'
Issuance of common shares pursuant to placement agent agreement (in shares)	'	7,500	'	'	'	'	'	'	'
Issuance of common shares pursuant to placement agent agreement	'	6	'	'	'	'	'	'	'
Warrants issued for services	'	'	'	'	'	0	'	'	'
Note discount arising from note conversion	'	'	'	'	'	0	'	'	'
Warrants issued in connection with convertible preferred units issued in private placement	'	'	'	0	'	'	'	'	'
Warrants issued in connection with note conversion	'	'	'	'	'	0	'	'	'
Reverse merger transaction - elimination of accumulated deficit	'	'	'	'	'	0	'	'	'
Reverse merger transaction -previously issued Laurier common stock (in shares)	'	'	'	'	'	137,525	'	'	'
Reverse merger transaction -previously issued Laurier common stock	'	'	'	'	'	110	'	'	'
Warrants issues to placement agents in connection with private placement	'	'	'	0	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock (in shares)	'	'	39,884	'	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock	'	'	32	'	'	'	'	'	'
Grant of restricted shares (in shares)	'	'	31,250	'	'	'	'	'	'
Grant of restricted shares	'	'	0	'	'	'	'	'	'
Stock option exercise (in shares)	'	'	6,231	'	2,500	'	'	'	'
Stock option exercise	'	'	5	'	2	'	'	'	'
Issuance of common shares in lieu of liquidated damages (in shares)	380,606	'	'	'	'	'	'	'	'
Issuance of common shares in lieu of liquidated damages	305	'	'	'	'	'	'	'	'
Net loss	0	0	0	0	'	'	0	0	'
Ending Balance (in shares)	20,370,331	4,545,618	4,538,118	2,551,503	2,551,503	2,549,003	1,246,100	1,246,100	20,370,331
Ending Balance	5,465	3,611	3,605	2,041	2,041	2,039	997	997	5,465
COMMON STOCK | Series C Warrant	'	'	'	'	'	'	'	'	'
Warrants issued for services	0	'	'	'	'	'	'	'	'
COMMON STOCK | Founders	'	'	'	'	'	'	'	'	'
Issuance of common shares (in share)	'	'	'	'	'	'	'	1,246,100	'
Issuance of common shares	'	'	'	'	'	'	'	997	'
COMMON STOCK | Private Placement	'	'	'	'	'	'	'	'	'
Issuance of common shares (in share)	8,413,354	'	'	'	'	920,086	'	'	'
Issuance of common shares	841	'	'	'	'	736	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770 (in share)	'	'	'	0	'	'	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770	'	'	'	0	'	'	'	'	'
COMMON STOCK | Notes Payable	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement (in share)	'	'	'	'	'	245,292	'	'	'
Conversion of notes payable upon closing of private placement	'	'	'	'	'	196	'	'	'
COMMON STOCK | PREFERRED	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement (in share)	'	'	1,909,250	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	1,527	'	'	'	'	'	'
Additional paid-in capital	'	'	'	'	'	'	'	'	'
Issuance of common shares	22,276,390	'	'	'	'	'	'	'	'
Stock based compensation for services	1,456,776	722,811	707,284	249,286	647,448	1,131,218	88,300	9,700	'
Issuance of common shares pursuant to placement agent agreement	'	43,494	'	'	'	'	'	'	'
Warrants issued for services	'	'	'	'	'	480,400	'	'	'
Note discount arising from note conversion	'	'	'	'	'	475,391	'	'	'
Warrants issued in connection with convertible preferred units issued in private placement	'	'	'	-3,340,421	'	'	'	'	'
Warrants issued in connection with note conversion	'	'	'	'	'	348,000	'	'	'
Reverse merger transaction - elimination of accumulated deficit	'	'	'	'	'	-120,648	'	'	'
Reverse merger transaction -previously issued Laurier common stock	'	'	'	'	'	120,538	'	'	'
Warrants issues to placement agents in connection with private placement	'	'	'	464,720	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock	'	'	-32	'	'	'	'	'	'
Grant of restricted shares	'	'	115,168	'	'	'	'	'	'
Stock option exercise	'	'	6,475	'	2,598	'	'	'	'
Issuance of common shares in lieu of liquidated damages	913,205	'	'	'	'	'	'	'	'
Net loss	0	0	0	0	'	'	0	0	'
Ending Balance	76,668,966	37,631,339	36,865,034	36,036,139	25,154,571	24,504,525	102,003	13,703	76,668,966
Additional paid-in capital | Series C Warrant	'	'	'	'	'	'	'	'	'
Warrants issued for services	5,233,844	'	'	'	'	'	'	'	'
Additional paid-in capital | Founders	'	'	'	'	'	'	'	'	'
Issuance of common shares	'	'	'	'	'	'	'	4,003	'
Additional paid-in capital | Private Placement	'	'	'	'	'	'	'	'	'
Issuance of common shares	9,157,412	'	'	'	'	17,689,301	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770	'	'	'	13,507,983	'	'	'	'	'
Additional paid-in capital | Notes Payable	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	'	'	'	4,278,322	'	'	'
Additional paid-in capital | PREFERRED	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	0	'	'	'	'	'	'
Deficit accumulated during the development stage	'	'	'	'	'	'	'	'	'
Issuance of common shares	0	'	'	'	'	'	'	'	'
Stock based compensation for services	0	0	0	0	0	0	0	0	'
Issuance of common shares pursuant to placement agent agreement	'	0	'	'	'	'	'	'	'
Warrants issued for services	'	'	'	'	'	0	'	'	'
Note discount arising from note conversion	'	'	'	'	'	0	'	'	'
Warrants issued in connection with convertible preferred units issued in private placement	'	'	'	0	'	'	'	'	'
Warrants issued in connection with note conversion	'	'	'	'	'	0	'	'	'
Reverse merger transaction - elimination of accumulated deficit	'	'	'	'	'	0	'	'	'
Reverse merger transaction -previously issued Laurier common stock	'	'	'	'	'	0	'	'	'
Warrants issues to placement agents in connection with private placement	'	'	'	0	'	'	'	'	'
Issuance of stock dividend in connection with conversion of preferred stock	'	'	0	'	'	'	'	'	'
Grant of restricted shares	'	'	0	'	'	'	'	'	'
Stock option exercise	'	'	0	'	0	'	'	'	'
Issuance of common shares in lieu of liquidated damages	0	'	'	'	'	'	'	'	'
Net loss	-39,656,975	-14,387,782	-7,909,113	-4,023,026	-6,936,705	-12,913,566	-3,359,697	-370,893	'
Ending Balance	-89,557,757	-49,900,782	-35,513,000	-27,603,887	-23,580,861	-16,644,156	-3,730,590	-370,893	-89,557,757
Deficit accumulated during the development stage | Series C Warrant	'	'	'	'	'	'	'	'	'
Warrants issued for services	0	'	'	'	'	'	'	'	'
Deficit accumulated during the development stage | Founders	'	'	'	'	'	'	'	'	'
Issuance of common shares	'	'	'	'	'	'	'	0	'
Deficit accumulated during the development stage | Private Placement	'	'	'	'	'	'	'	'	'
Issuance of common shares	0	'	'	'	'	0	'	'	'
Convertible preferred units issued in private placement, net of issuance costs of $1,299,770	'	'	'	0	'	'	'	'	'
Deficit accumulated during the development stage | Notes Payable	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	'	'	'	0	'	'	'
Deficit accumulated during the development stage | PREFERRED	'	'	'	'	'	'	'	'	'
Conversion of notes payable upon closing of private placement	'	'	$0	'	'	'	'	'	'

CONDENSED_STATEMENT_OF_STOCKHO1

CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2008	Dec. 31, 2006	Dec. 31, 2013
		COMMON STOCK	COMMON STOCK	COMMON STOCK
				Private Placement
Issuance of common shares to founder	'	'	$0.00	'
Stock issuance costs	$1,299,770	$141,646	'	$766,803

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities	'	'	'
Net loss	($39,656,975)	($14,387,782)	($89,557,757)
Adjustment to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation and amortization	13,117	13,836	128,097
Stock-based compensation	1,456,776	722,811	5,127,991
Change in fair value of derivative liability	4,166,454	-2,806,750	1,724,755
Write-off of intangible assets	0	0	85,125
Warrants issued for services	0	0	480,400
Warrants issued in connection with note conversion	0	0	348,000
Note discount arising from beneficial conversion feature	0	0	475,391
Deferred rent	-4,914	5,360	7,797
Loss on disposal of assets	0	0	5,357
Noncash interest expense	18,996,553	6,255,996	25,564,067
Changes in operating assets and liabilities	'	'	'
Prepaid expenses and other current assets	117,250	93,432	-86,266
Security deposit	0	0	-10,455
Accounts payable	1,388,844	869,993	2,941,998
Accrued expenses	-717,452	-130,170	340,419
Due to related party	-2,229	-56,488	26,039
Net cash used in operating activities	-14,242,576	-9,419,762	-52,399,042
Cash flows from investing activities	'	'	'
Purchase of property and equipment	0	0	-100,174
Cash paid for intangible assets	0	0	-85,125
Proceeds from related party advance	0	0	525,000
Repayment of related party advance	0	0	-525,000
Net cash used in investing activities	0	0	-185,299
Cash flows from financing activities	'	'	'
Proceeds from issuance of common stock to founders	0	0	5,000
Proceeds from issuance of preferred stock in private placement, net	0	0	13,974,230
Proceeds from issuance of units in private placement, net	19,425,340	0	37,115,377
Deferred financing fees paid	0	-1,172,345	-1,217,345
Proceeds from issuance of notes payable	0	0	1,000,000
Repayment of notes payable	0	0	-1,000,000
Proceeds from issuance of convertible notes payable	0	0	3,967,000
Proceeds from issuance of convertible debentures payable	0	14,857,200	14,857,200
Proceeds from issuance of warrants	10,648,002	0	10,648,002
Proceeds from exercise of stock options	0	0	9,080
Net cash provided by financing activities	30,073,342	13,684,855	79,358,544
Net increase in cash and cash equivalents	15,830,766	4,265,093	26,774,203
Cash and cash equivalents at beginning of period	10,943,437	6,678,344	0
Cash and cash equivalents at end of period	26,774,203	10,943,437	26,774,203
Supplemental schedule of cash flows information:	'	'	'
Cash paid for interest	157,284	105,034	342,318
Supplemental schedule of non-cash investing and financing activities:	'	'	'
Conversion of debentures into common stock	14,293	0	14,293
Conversion of notes payable and interest to common stock	0	0	4,278,518
Common shares of Laurier issued in reverse merger transaction	0	0	110
Issuance of common shares in lieu of liquidated damages	913,510	0	913,510
Issuance of common shares in lieu of accrued and additional interest	2,016,804	0	2,016,804
Issuance of warrants in connection with private placement of convertible preferred units	0	0	3,340,421
Issuance of warrants in connection with private placement of convertible debentures	0	12,973,055	12,973,055
Issuance of common stock pursuant to placement agent agreement	0	43,500	43,500
Preferred stock dividends settled in common stock	$0	$0	$319,074

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2013
Business Combination, Description [Abstract]	'
DESCRIPTION OF BUSINESS	'
	1. DESCRIPTION OF BUSINESS
	Arno Therapeutics, Inc. (“Arno” or the “Company”) develops innovative drug candidates intended to treat patients with cancer. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95% of the outstanding common stock of Laurier, assuming the issuance of all shares issuable upon the exercise of outstanding options and warrants, and all of the officers and directors of Old Arno in office immediately prior to the Merger were appointed as the officers and directors of Laurier immediately following the Merger. Further, Laurier was a non-operating shell company prior to the Merger. The merger of a private operating company into a non-operating public shell corporation with nominal net assets is considered to be a capital transaction in substance, rather than a business combination, for accounting purposes. Accordingly, the Company treated this transaction as a capital transaction without recording goodwill or adjusting any of its other assets or liabilities. All costs incurred in connection with the Merger have been expensed. Upon completion of the Merger, the Company adopted Old Arno’s business plan.

LIQUIDITY_AND_CAPITAL_RESOURCE

LIQUIDITY AND CAPITAL RESOURCES	12 Months Ended
	Dec. 31, 2013
Working Capital Information [Abstract]	'
LIQUIDITY AND CAPITAL RESOURCES	'
	2. LIQUIDITY AND CAPITAL RESOURCES
	Cash resources as of December 31, 2013 were approximately $26.8 million, compared to approximately $10.9 million as of December 31, 2012. Based on its resources at December 31, 2013, and the current plan of expenditure on continuing development of the Company’s current product candidates, the Company believes that it has sufficient capital to fund its operations through the first quarter of 2015. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs.
	The long-term success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of its stock or other securities, issuing additional indebtedness or by licensing the rights to one or more of its product candidates to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations beyond the first quarter of 2015, management can provide no assurances that the Company will be successful in raising sufficient funds.
	In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.

THE_MERGER_AND_BASIS_OF_PRESEN

THE MERGER AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2013
Mergers Acquisitions And Dispositions Disclosures [Abstract]	'
THE MERGER AND BASIS OF PRESENTATION	'
	3. THE MERGER AND BASIS OF PRESENTATION
	The accompanying audited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the instructions to Form 10-K promulgated by the Securities and Exchange Commission (“SEC”).
	(a) Description of the Merger and Private Placement Offering
	The Company completed the Merger on June 3, 2008.   In accordance with the terms of the Merger, each share of common stock of Old Arno that was outstanding immediately prior to the Merger was exchanged for 1.99377 shares of the Company’s common stock.  In addition, all securities convertible into or exercisable for shares of Old Arno common stock outstanding immediately prior to the Merger were cancelled, and the holders thereof received similar securities convertible into or exercisable for the purchase of an aggregate of 1,611,760 shares of the Company’s common stock. In consideration for their shares of the Company’s pre-merger common stock, the Company’s shareholders received an aggregate of 19,291,824 shares of Laurier common stock.  Immediately prior to the effective time of the Merger, 1,100,200 shares of Laurier’s common stock were issued and outstanding. Upon completion of the Merger, the Old Arno shareholders owned approximately 95% of the Company’s issued and outstanding common stock, assuming the exercise of all of the issued and outstanding common stock options and warrants.
	Following the Merger, the business conducted by the Company is the business conducted by Old Arno prior to the Merger. In addition, the directors and officers of Laurier were replaced by the directors and officers of Old Arno.
	As a condition and immediately prior to the closing of the Merger, on June 2, 2008, Old Arno completed a private placement of its equity securities whereby it received gross proceeds of approximately $17,732,000 through the sale of approximately 3,691,900 shares of Old Arno Common Stock to selected accredited investors, which shares were exchanged for approximately 7,360,700 shares of Company Common Stock after giving effect to the Merger. Contemporaneously with the June 2008 private placement, the Old Arno’s outstanding 6% Notes converted into 984,246 shares of Old Arno’s common stock and the holders of the Notes received warrants to purchase an aggregate of 98,409 shares of Old Arno common stock at an exercise price equal to $4.83 per share. The shares issued upon conversion were exchanged for an aggregate of approximately 1,962,338 shares of the Company’s Common Stock and the warrants were exchanged for five-year warrants to purchase an aggregate of approximately 196,189 shares of the Company’s Common Stock at an exercise price equal to $2.42 per share.
	All references to share and per share amounts in these financial statements have been restated to retroactively reflect the number of common shares of Arno common stock issued pursuant to the Merger.
	(b) Accounting Treatment of the Merger; Financial Statement Presentation
	The Merger was accounted for as a reverse acquisition pursuant to Accounting Standards Codification (“ASC”) 805-40-25, which provides that the “merger of a private operating company into a non-operating public shell corporation with nominal net assets typically results in the owners and management of the private company having actual or effective operating control of the combined company after the transaction, with the shareholders of the former public shell continuing only as passive investors. These transactions are considered by the Securities and Exchange Commission to be capital transactions in substance, rather than business combinations. That is, the transaction is equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation, accompanied by a recapitalization.” Accordingly, the Merger has been accounted for as a recapitalization, and, for accounting purposes, Old Arno is considered the acquirer in a reverse acquisition.
	Laurier’s  historical accumulated deficit for periods prior to June 3, 2008, in the amount of $120,538, was eliminated against additional-paid-in-capital, and the accompanying financial statements present the previously issued shares of Laurier common stock as having been issued pursuant to the Merger on June 3, 2008. The shares of common stock of the Company issued to the Old Arno stockholders in the Merger are presented as having been outstanding since August 2005 (the month when Old Arno first sold its equity securities).
	Because the Merger was accounted for as a reverse acquisition under GAAP, the financial statements for periods prior to June 3, 2008 reflect only the operations of Old Arno.
	(c) Reverse Stock Split
	Effective as of the close of business on October 29, 2013, the Company amended its Amended and Restated Certificate of Incorporation to effect a combination (“Reverse Stock Split”) of the Common Stock at a ratio of one-for-eight.  All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) Use of Estimates
	The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees, directors and consultants, valuation of derivatives and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
	(b) Cash and Cash Equivalents
	The Company considers all highly liquid investments with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.
	(c) Deferred Financing Fees
	Finance costs relating to debt issued are recorded as a deferred charge and amortized to interest expense over the expected term of the debt using the effective interest method.
	(d) Prepaid Expenses
	Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, insurance policies and license fees. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight line method.
	(e) Property and Equipment
	Property and equipment consist primarily of furnishings, fixtures, leasehold improvements and computer equipment and are recorded at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter.
	Description		Estimated Useful Life
	Office equipment and furniture		5 to 7 years
	Leasehold improvements		3 years
	Computer equipment		3 years
	(f) Fair Value of Financial Instruments
	The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and derivative liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
	(g) Convertible Debentures and Warrant Liability
	The Company accounts for the convertible debentures and warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 10) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
	(h) Concentration of Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and is insured to the maximum limitations. Balances in these accounts may exceed federally insured limits at times, which expose the Company to institutional risk.
	(i) Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
	(j) Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Share-based compensation is recognized only for those awards that are ultimately expected to vest.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model.  The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.
	(k) Loss per Common Share
	Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
	As of December 31, 2013, potentially dilutive securities include:
		December 31, 2013
	Warrants to purchase common stock			34,181,166
	Options to purchase common stock			5,594,151
	Total potentially dilutive securities			39,775,318
	There were no potentially dilutive securities as of December 31, 2012.
	For the year ended December 31, 2013 and 2012, 13,966,897 and 20,726,257 options, warrants and convertible debentures have been excluded from the computation of potentially dilutive securities, respectively, as their exercise prices are greater than the fair market price per common share as of December 31, 2013 and 2012, respectively.
	(l) Comprehensive Loss
	The Company has no components of other comprehensive loss other than its net loss, and accordingly, comprehensive loss is equal to net loss for all periods presented.
	(m) Income Taxes
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the period in which the differences are expected to affect taxable income. The Company provides a valuation allowance when it appears more likely than not that some or all of the net deferred tax assets will not be realized. The Company has not performed an Internal Revenue Section 382 limitation study. Depending on the outcome of such study, the gross amount of net operating losses recognized in future tax periods could be limited.
	A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded.
	The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2013 and 2012 respectively. In addition, the Company had no amounts accrued for interest and penalties as of December 31, 2013 and 2012, respectively.
	(n) Recently Issued Accounting Pronouncements
	Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	5. PROPERTY AND EQUIPMENT
	Property and equipment as of December 31, 2013 and 2012 consist of the following:
		2013		2012
	Computer equipment and software	$	17,721	$	17,721
	Office furniture and equipment		52,242		52,242
	Leasehold improvements		8,449		8,449
	Total property and equipment		78,412		78,412
	Accumulated depreciation		-66,692		-53,575
	Total property and equipment, net	$	11,720	$	24,837
	Depreciation expense for the years ended December 31, 2013 and 2012, and the period from August 1, 2005 (inception) through December 31, 2013, was $13,117, $13,836 and $83,096, respectively.

INTANGIBLE_ASSETS_AND_INTELLEC

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	'
	6. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY
	License Agreements
	Onapristone License Agreement
	The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of France; provided, however, that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration.
	The onapristone license agreement provides the Company with exclusive, worldwide rights to a United States provisional patent application that relates to assays for predictive biomarkers for anti-progestin efficacy. The Company intends to expand its patent portfolio by filing additional patent applications covering the use of onapristone and/or a companion diagnostic product. If the pending patent application issues, the issued patent would be scheduled to expire in 2031.
	The Company made a one-time cash payment of $500,000 to Invivis upon execution of the license agreement on February 13, 2012. Additionally, Invivis will receive performance-based cash payments of up to an aggregate of $15.1 million upon successful completion of clinical and regulatory milestones relating to onapristone, which milestones include the marketing approval of onapristone in multiple indications in the United States or the European Union as well as Japan. The first milestone was due upon the dosing of the first patient in a pharmacokinetic study and was achieved during August 2013 and the Company made a $150,000 payment to Invivis during October 2013. The Company made its next milestone payment to Invivis upon the dosing of the first subject in the first Company-sponsored Phase I clinical trial of onapristone. The first patient was dosed in January 2014. In addition, the Company will pay Invivis low single digit sales royalties based on net sales of onapristone by the Company or any of its sublicensees. Pursuant to a separate services agreement which expired in February 2014, Invivis provided the Company with certain clinical development support services, which includes the assignment of up to two full-time employees to perform such services, in exchange for a monthly cash payment of approximately $70,833. The Company is currently in discussions with Invivis to renew this services agreement.
	Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032. In general, Invivis may terminate the license agreement at any time upon a material breach by the Company to the extent the Company fails to cure any such breach within 90 days after receiving notice of such breach or in the event the Company files for bankruptcy. The Company may terminate the agreement for any reason upon 90 days’ prior written notice.
	AR-12 and AR-42 License Agreements
	The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses.
	In 2008, pursuant to the Company’s license agreements for AR-12 and AR-42, the Company made one-time cash payments to Ohio State in the aggregate amount of $450,000 and reimbursed it for past patent expenses. Additionally, the Company is required to make performance-based cash payments upon successful completion of clinical and regulatory milestones relating to AR-12 and AR-42 in the United States, Europe and Japan. The license agreements for AR-12 and AR-42 provide for aggregate potential milestone payments of up to $6.1 million for AR-12, of which $5.0 million is due only after marketing approval in the United States, Europe and Japan, and $5.1 million for AR-42, of which $4.0 million is due only after marketing approval in the United States, Europe and Japan.  In September 2009, the Company paid Ohio State a milestone payment upon the commencement of the first Company-sponsored Phase I clinical study of AR-12.  The first milestone payment for AR-42 will be due when the first patient is dosed in the first Company-sponsored clinical trial, which is not expected to occur in 2013. Pursuant to the license agreements for AR-12 and AR-42, the Company must pay Ohio State royalties on net sales of licensed products at rates in the low-single digits. To the extent the Company enters into a sublicensing agreement relating to either or both of AR-12 or AR-42, the Company will be required to pay Ohio State a portion of all non-royalty income received from such sublicensee. The Company was not required to make any milestone payments during 2013 and does not expect to be required to make any milestone payments under these license agreements during 2014.
	The license agreements with Ohio State further provide that the Company will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42 each expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 years after the effective date of the license. Ohio State will generally be able to terminate either license upon the Company’s breach of the terms of the license to the extent the Company fails to cure any such breach within 90 days after receiving notice of such breach or the Company files for bankruptcy. The Company may terminate either license upon 90 days prior written notice.
	AR-67 License Agreement
	In January 2012, the Company received a notice from the University of Pittsburgh, (“Pitt”) claiming that the Company was in default under its license agreement relating to AR-67 for failure to pay a $250,000 annual license fee under the terms of that agreement and providing the Company with 60 days’ notice to remedy the default. On March 29, 2012, following the Company’s determination not to proceed with further development of AR-67, the Company agreed with Pitt to terminate the license agreement. In February 2013, Pitt commenced an action in the Court of Common Pleas of Allegheny County, Pennsylvania, seeking damages of $250,000, plus interest and costs, based on its claim that the Company breached the license agreement by failing to pay the annual license fee. On March 28, 2013, the Company entered into a settlement agreement with Pitt pursuant to which the Company agreed to pay $235,000 in full satisfaction of all remaining obligations under the license agreement, which payment was made on April 2, 2013.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
ACCRUED LIABILITIES	'
	7. ACCRUED LIABILITIES
	Accrued liabilities as of December 31, 2013 and 2012 consist of the following:
		2013		2012
	Accrued compensation and related benefits	$	439,156	$	304,772
	Accrued research and development expense		316,099		713,099
	Accrued liquidated damages		-		594,288
	Accrued other expense		170,000		40,000
	Total accrued liabilities	$	925,255	$	1,652,159

CONVERTIBLE_DEBENTURES

CONVERTIBLE DEBENTURES	12 Months Ended
	Dec. 31, 2013
Convertible Longterm Notes Payable Current And Noncurrent [Abstract]	'
CONVERTIBLE DEBENTURES	'
	8. CONVERTIBLE DEBENTURES
	On November 26, 2012, the Company entered into a Securities Purchase Agreement, with a number of institutional and accredited investors (as amended, the “2012 Purchase Agreement”) pursuant to which the Company sold in a private placement an aggregate principal amount of $14,857,200 of three-year 8% Senior Convertible Debentures(“the Debentures”). In accordance with the 2012 Purchase Agreement, the Company also issued five-year Series A warrants to purchase an aggregate of 6,190,500 shares of common stock at an initial exercise price of $4.00 per share (the “Series A Warrants”) and 18-month Series B warrants to purchase an aggregate of 6,190,500 shares of common stock at an initial exercise price of $2.40 per share (the “Series B Warrants” and together with the Series A Warrants, the “2012 Warrants”). The sale of the Debentures and 2012 Warrants, which occurred in two closings on November 26, 2012 and December 18, 2012, resulted in aggregate gross proceeds of approximately $14.9 million, before deducting placement agent fees and other transaction-related expenses of approximately $1.2 million. The 2012 Warrants were valued at $12,430,524 on issuance and recorded as a debt discount.
	The conversion price of the Debentures was subject to a “full-ratchet” anti-dilution provision, such that in the event the Company makes an issuance of common stock (subject to customary exceptions) at a price per share less than the applicable exercise price of the Debentures, the applicable conversion price will be reduced to the price per share applicable to such new issuance. However, after such time as the Company has raised at least $12 million in subsequent equity financings, the conversion price of the Debentures will be subject to a customary weighted-average price adjustment with respect to new issuances. This conversion feature of the Debentures is considered an embedded derivative and was accounted for separately from the Debentures and was valued at $7,548,500 on issuance and recorded as a debt discount.
	The following table reflects the debt discount for the 2012 Warrants and the embedded conversion feature of the Debentures at their fair values on issuance:
		Issuance
	Debentures, principal			14,857,200
	2012 Warrant liability			-12,430,524
	Debenture conversion feature			-7,548,500
				-5,121,824
	The excess fair value over proceeds on the date of issuance of approximately $5.1 million was recorded in interest expense on the statement of operations on the issuance. As of December 31, 2013 and December 31, 2012, the Company recorded amortization on the debt discount of approximately $14.9 million and $0.5 million, respectively, to interest expense. As a result of the Conversion Agreement, as discussed below, the Company accelerated the amortization of the remaining balance of debt discount of approximately $10.6 million on October 29, 2013 as the underlying debentures converted into common shares.
	On October 29, 2013, the Company also entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Holders”) of its Debentures.
	Pursuant to the Conversion Agreement, the Holders agreed to convert the entire outstanding principal amount of their Debentures, together with accrued and unpaid interest through October 29, 2013, into shares of the Company’s common stock at a conversion price of $2.40 per share for a total of approximately 6,530,154 shares, of which 345,606 shares were issued for the accrued and unpaid interest. As a result of such conversion, all of the Company’s obligations under the Debentures are fully satisfied.
	As additional consideration for their agreement to convert the Debentures, the Company provided each Holder with one year of additional accrued interest at 8% per annum at conversion and extended the term of the Series B Warrants issued to the Holders in connection with their initial purchase of the Debentures to October 31, 2014. The additional year of accrued interest was satisfied by the issuance of shares of common stock at a price of $2.40 per share for a total additional issuance of approximately 494,764 shares of common stock. The Company recorded the inducement to convert the debentures as additional interest expense in the amount of approximately $1,187,433.
	Pursuant to the terms of a Registration Rights Agreement entered into on November 26, 2012 in connection with the 2012 Purchase Agreement, the Company agreed to file a registration statement under the Securities Act of 1933, as amended, covering the resale of: (i) 100% of the shares of common stock issuable as payment of accrued interest under the Debentures and upon exercise of the Series A Warrants; and (ii) 150% of the shares of common stock issuable upon conversion of the Debentures and upon exercise of the Series B Warrants (collectively, the “Registrable Securities”). The Company further agreed to cause such registration statement to be filed within 30 days following the date of the Registration Rights Agreement, or by December 26, 2012, and to cause such registration statement to be declared effective within 60 days following the date of the Registration Rights Agreement, or by January 25, 2013, or, if the registration statement was subject to review by the SEC, to cause such registration statement to be declared effective within 120 days following the date of the Registration Rights Agreement, or by March 26, 2013. If such registration statement, covering 100% of the Registrable Securities, was not declared effective by the SEC by the applicable date, the Company agreed to pay liquidated damages to the investors in the amount of 2% of each investor’s aggregate investment amount per month until the registration statement is declared effective or until such earlier time as the Registrable Securities may be traded pursuant to Rule 144.
	On December 26, 2012, the Company filed a registration statement seeking to register 100% of the Registrable Securities. However, the SEC determined that the number of shares the Company was seeking to register exceeded the limitations imposed by the SEC under Rule 415, and the Company was thus unable to register a significant amount of the Registrable Securities. As a result of the SEC’s determination, the Company amended the registration statement to reduce the number of Registrable Securities covered thereby by including only the shares issuable upon exercise of the Series B Warrants. As amended, the registration statement was declared effective by the SEC on April 18, 2013. Accordingly, because a registration statement covering 100% of the Registrable Securities was not declared effective by March 26, 2013, the investors each became entitled to liquidated damages in the amount of 2% of their investment amount per month, payable on March 27, 2013 and on each monthly anniversary thereafter until the Registrable Securities may be traded pursuant to Rule 144. Because the Registrable Securities could be resold by their holders under Rule 144 six months after the applicable closing date under the 2012 Purchase Agreement, the Company was required to pay the investors approximately three months’ of liquidated damages, or approximately $0.9 million in the aggregate.
	On March 25, 2013, the Company and holders of approximately 80% of the principal amount of Debentures entered into an amendment to the Registration Rights Agreement, permitting the Company, in its sole discretion, to elect to pay liquidated damages resulting from the Company’s failure to successfully cause the registration statement covering the resale of 100% of the Registrable Securities to be declared effective by the SEC by March 26, 2013, by issuing shares of common stock in lieu of cash. If electing to issue shares in lieu of paying cash, the Company agreed to issue to each investor a number of shares of common stock equal to (a) the aggregate amount of liquidated damages that the Company is electing to pay to such investor in the form of shares, divided by (b) $2.40. Pursuant to the terms of the Registration Rights Agreement, because holders of over two-thirds of the Debentures consented in writing to the March 25, 2013 amendment, such amendment is binding on all holders of Registrable Securities. On March 27, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued shares of common stock to the investors in lieu of an aggregate cash payment of $297,148, representing the first installment of liquidated damages under the Registration Rights Agreement, as amended. On April 29, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued additional shares of common stock to the investors in lieu of an aggregate cash payment of $327,688, representing the second installment of liquidated damages under the Registration Rights Agreement, as amended.
	In May 2013, the Company determined that investors were entitled to additional liquidated damages arising from the 2012 Purchase Agreement in the amount of $288,674.  The Company assessed that this amount should have been accrued in 2012 as part of the issuance. The Company determined that the impact of not reflecting this in 2012 was not material to the 2012 financial statements and has reflected this as interest expense in the first quarter of 2013.  This expense resulted in the issuance of additional shares and a non-cash charge in 2013. On May 27, 2013, the Company issued shares of common stock to the investors in lieu of an aggregate cash payment of $288,674, representing the third and final installment of liquidated damages under the Registration Rights Agreement, as amended. The aggregate number of shares issued in lieu of cash payments for liquidated damages under the Debentures was 380,606 shares of common stock.
	In March 2013, the Company sought the agreement of the Debenture holders to amend their respective Debentures to provide for the accrual of all interest payments under such Debentures until the applicable maturity date in November or December of 2015, with such interest accruing at the rate of 8% per annum, compounding quarterly. As of October 29, 2013, the date of the Conversion Agreement, the Company had entered into such amendments with the holders of Debentures in the aggregate principal amount of $12,230,000. In connection with the Conversion Agreement, all of the accrued interest on the Debentures were converted into 345,606 shares of common stock.
	The following table illustrates the components of total interest expense for 2013 and 2012 incurred under the Debentures.
			Year Ended
			December 31,
	Interest Expense		2013		2012
	Note conversion discount		$	14,366,161	$	5,612,863
	Interest expense on 2012 debentures			2,174,244		104,034
	Amortized deferred financing fees			1,709,531		48,844
	Liquidated damages on 2012 debentures			319,221		594,288
	Total Interest Expense		$	18,569,157	$	6,360,029

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	9. FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of December 31, 2013.
	The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
		•	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
		•	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
		•	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2013:
						Quoted Market
						Prices in Active			Significant Other		Significant
			Fair Value			Markets			Observable Inputs		Unobservable Inputs
			December 31, 2013			(Level 1)			(Level 2)		(Level 3)
	Liabilities
	Warrant liability - 2010 Series B		$	362,452		$	-		$	-	$	362,452
	Warrant liability - 2012 placement agent			362,633			-			-		362,633
	Warrant liability - 2012 Series A&B			16,703,984								16,703,984
	Warrant liability - 2013 placement agent			98,080			-			-		98,080
	Warrant liability - 2013 Series D&E			18,337,732			-			-		18,337,732
	Total		$	35,864,881		$	-		$	-	$	35,864,881
	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2012:
						Quoted Market
						Prices in Active			Significant Other		Significant
			Fair Value			Markets			Observable Inputs		Unobservable Inputs
			December 31, 2012			(Level 1)			(Level 2)		(Level 3)
	Liabilities
	Warrant liability - 2010 Series B		$	898,722		$	-		$	-	$	898,722
	Debenture conversion feature - 2012			7,548,500			-			-		7,548,500
	Warrant liability - 2012 placement agent			542,530			-			-		542,530
	Warrant liability - 2012 Series A&B			12,430,524			-			-		12,430,524
	Total		$	21,420,276		$	-		$	-	$	21,420,276
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at December 31, 2013:
	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
						2013 Series			2012 Series
						D&E and			A&B and				Debenture
			Total Warrant			Placement			Placement				Conversion
			Liability			Agent			Agent		2010 Series B		Feature
	Balance at January 1, 2012		$	3,705,472							$	3,705,472
	Purchase, sales and settlements:
	Warrants and other derivatives issued			20,521,554						12,973,054				7,548,500
	Total gains or losses:
	Unrealized depreciation			-2,806,750								-2,806,750
	Balance at January 1, 2013		$	21,420,276		$	-		$	12,973,054	$	898,722	$	7,548,500
	Purchase, sales and settlements:
	Warrants and other derivatives issued			15,681,151			15,681,151
	Settlement of derivatives			-5,403,000										-5,403,000
	Total gains or losses:
	Unrealized depreciation			4,166,454			2,754,662			4,093,562		-536,270		-2,145,500
	Balance at December 31, 2013		$	35,864,881		$	18,435,813		$	17,066,616	$	362,452	$	-
	Value per Warrant		$	0.75		$	0.61		$	1.02	$	0.39
	Significant assumptions used at December 31, 2013 and 2012 for the warrants and embedded conversion discount derivative liability of the Debentures are as follows:
		December 31, 2013				December 31, 2012
	Volatility			108	%			200	%
	Risk-free interest rate			2.08	%			1.05	%

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	10. STOCKHOLDERS’ EQUITY
	Common Stock
	The Company amended its Amended & Restated Certificate of Incorporation, effective as of October 29, 2013, to effect a combination of its common stock at a ratio of 1-for-8 (the “Reverse Split”). The Reverse Split was effective immediately prior to the entry into the Purchase Agreement. The Reverse Split was authorized by the stockholders of the Company on November 10, 2010.
	As a result of the Reverse Split, all references to common stock, stock options and warrants and other securities convertible into common stock, and per share amounts for all prior periods presented have been retroactively restated to reflect the 1-for-8 reverse stock split of common stock.
	On November 21, 2012, the Company amended its Amended & Restated Certificate of Incorporation to increase the number of shares of common stock that the Company is authorized to issue from 80,000,000 shares to 500,000,000 shares.
	On March 27, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued an aggregate of approximately 123,809 shares of common stock to the investors in lieu of an aggregate cash payment of $297,144, representing the first installment of liquidated damages under the Registration Rights Agreement, as amended.
	On April 29, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued an aggregate of approximately 136,536 shares of common stock to the investors in lieu of an aggregate cash payment of $327,688, representing the second installment of liquidated damages under the Registration Rights Agreement, as amended.
	On May 27, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued an aggregate of approximately 120,280 shares of common stock to the investors in lieu of an aggregate cash payment of $288,674, representing the third and final installment of liquidated damages under the Registration Rights Agreement, as amended.
	As of December 31, 2013, the Company had 20,370,331 shares of common stock issued and outstanding and approximately 53,742,215 shares of common stock reserved for issuance upon the exercise of outstanding options and warrants.
	On October 29, 2013, the Company entered into a Securities Purchase Agreement (the “2013 Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company sold and the Purchasers purchased, an aggregate of 12,868,585 units of the Company’s securities (the “Units”), with each Unit consisting of the following:
		(i)	either (a) one share of common stock (each a “Share,” and collectively, the “Shares”), or (b) a five-year common stock warrant to purchase one share of common stock (collectively, the “Series C Warrant Shares”) at an exercise price of $0.01 per share (collectively, the “Series C Warrants”);
		(ii)	a five-year warrant to purchase one share of common stock (collectively, the “Series D Warrant Shares”) at an exercise price of $4.00 per share (collectively, the “Series D Warrants”); and
		(iii)	a warrant, expiring on October 31, 2014, to purchase one share of common stock (collectively, the “Series E Warrant Shares,” and together with the Series C Warrant Shares and the Series D Warrant Shares, the “Warrant Shares”) at an exercise price of $2.40 per share (collectively, the “Series E Warrants,” and together with the Series C Warrants and the Series D Warrants, the “2013 Warrants”).
	The Company sold and issued 8,413,354 Units consisting of Shares, Series D Warrants and Series E Warrants at a purchase price of $2.40 per Unit, and 4,455231 Units consisting of Series C Warrants, Series D Warrants and Series E Warrants at a purchase price of $2.39 per Unit, for total gross proceeds to the Company of $30.84 million, before deducting fees and other transaction related expenses of approximately $760,000. A closing of the sale of 12,826,752 Units was completed on October 29, 2013, and the sale of the remaining 41,833 Units was completed on October 30, 2013.
	The Purchase Agreement contains customary representations, warranties and covenants by each of the Company and the Purchasers. In addition, the Purchase Agreement provides that each Purchaser has a right, subject to certain exceptions described in the agreement, to participate in future issuances of equity and debt securities by the Company for a period of 18 months following the effective date of the Registration Statement (defined below).
	Contemporaneously with the entry into the Purchase Agreement, and as contemplated thereby, the Company entered into a Registration Rights Agreement with the Purchasers. Pursuant to the terms of the Registration Rights Agreement, the Company agreed to file, on or before December 30, 2013 (the “Filing Date”), a registration statement under the Securities Act covering the resale of the Shares and Warrant Shares (the “Registration Statement”), and to cause such Registration Statement to be declared effective by the Commission as soon as practicable thereafter, but not later than 120 days following the date of the Registration Rights Agreement (the “Effectiveness Date”). The Registration Statement was declared effective on January 27, 2014. The Company is required to maintain the effectiveness of the Registration Statement until all of the shares covered thereby are sold or may be sold pursuant to Rule 144 under the Securities Act without volume or manner of- sale restrictions and without the requirement that the Company be in compliance with the current public information requirements of Rule 144.
	Warrants
	In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 shares of Series A Preferred Stock at an initial exercise price of $8.00 per share (the “2010 Class A Warrants”) and five-year Class B warrants to purchase an aggregate of 801,885 shares of Series A Preferred Stock at an initial exercise price of $9.20 per share the “2010 Class B Warrants,” and together with the 2010 Class A Warrants, the “2010 Warrants”). Upon the automatic conversion of the Series A Preferred Stock in January 2011, the 2010 Warrants automatically converted to the right to purchase an equal number of shares of common stock. The terms of the warrants contain an anti-dilutive price adjustment provision, such that, in the event the Company issues common shares at a price below the current exercise price of the 2010 Warrants, the exercise price will be decreased pursuant to a customary “weighted-average” formula. In accordance with this provision and as a result of the issuances made pursuant to the 2012 Purchase Agreement and 2013 Purchase Agreement, the exercise price of the 2010 Class B warrants has been adjusted to $3.55 per share. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used.  Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $0.4 million and approximately $0.9 million at December 31, 2013 and December 31, 2012, respectively. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. This valuation is revised on a quarterly basis until the warrants are exercised or they expire with the changes in fair value recorded in other income (expense) on the statement of operations. The 2010 Class A warrants, representing the right to purchase an aggregate of 152,704 shares of common stock, expired during the year ended December 31, 2013 unexercised.
	Pursuant to the 2012 Purchase Agreement, the Company issued five-year Series A warrants to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $4.00 per share and 18-month Series B warrants to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $2.40 per share. The terms of the 2012 Warrants contain a “full-ratchet” anti-dilutive price adjustment provision. In accordance with such full-ratchet anti-dilution provision, in the event that the Company sells or issues additional shares of common stock, including securities convertible or exchangeable for common stock (subject to customary exceptions), at a per share price less than the applicable 2012 Warrant exercise price, such warrant exercise price will be reduced to an amount equal to the issuance price of such subsequently issued shares; after such time as the Company has raised at least $12 million in additional equity financing, the 2012 Warrants are subject to further anti-dilution protection based on a weighted-average formula. Further, the anti-dilution provisions of the 2012 Warrants provide that, in addition to a reduction in the applicable exercise price, the number of shares purchasable thereunder is increased such that the aggregate exercise price of the warrants (exercise price per share multiplied by total number of shares underlying the warrants) remained unchanged. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used.  Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $16.7 million and $12.4 million at December 31, 2013 and December 31, 2012, respectively.
	In connection with the 2012 offering of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim Group, to serve as placement agent. In consideration for its services, the Company paid Maxim Group a placement fee of $1,035,000. In addition, the Company issued to Maxim Partners LLC, or Maxim Partners, an affiliate of Maxim Group, 7,500 shares of common stock and five-year warrants to purchase an additional 283,750 shares of common stock at an initial exercise price of $2.64 per share. The warrants issued to Maxim Partners are in substantially the same form as the Warrants issued to the investors, except that they do not include certain anti-dilution provisions contained in the Warrants. However, the placement warrants do contain a provision that could require the Company to repurchase the warrants from the holder under certain conditions. Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $0.4 million and $0.5 million at December 31, 2013 and December 31, 2012, respectively.
	Under the terms of the 2013 Purchase Agreement, each Purchaser had the option to elect to receive a Series C Warrant in lieu of a Share in connection with each Unit it purchased. The Series C Warrants have a five-year term and are exercisable at an initial exercise price of $0.01 per share. The Series D Warrants have a five-year term and are exercisable at an initial exercise price of $4.00 per share, subject to adjustment for stock splits, combinations, recapitalization events and certain dilutive issuances (as described below). The Series E Warrants are exercisable until October 31, 2014 at an initial exercise price of $2.40 per share, subject to adjustment for stock splits, combinations, recapitalization events and certain dilutive issuances (as described below). The applicable exercise price of the Series D Warrants and Series E Warrants (but not the Series C Warrants) is subject to a weighted-average price adjustment in the event the Company makes future issuances of common stock or rights to acquire common stock (subject to certain exceptions) at a per share price less than the applicable warrant exercise price. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used.  Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability for the Series D and Series E Warrants to be approximately $15.7 million upon issuance at October 29, 2013 and $18.3 million at December 31, 2013.
	The 2013 Warrants are required to be exercised for cash, provided that if during the term of the Warrants there is not an effective registration statement under the Securities Act covering the resale of the shares issuable upon exercise of the Warrants, then the Warrants may be exercised on a cashless (net exercise) basis.
	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2013.
	Grant Date	Warrants Issued			Exercise		Weighted		Expiration	Exercised	Warrants
					Price		Average		Date		Outstanding
							Exercise
							Price
	9/3/10			801,885	$	3.55	$	2.82	9/3/15	-	801,885
	9/3/10			132,116	$	8.8	$	8.8	9/3/15	-	132,116
	11/26/12			5,293,738	$	2.4	$	2.4	10/31/14	-	5,293,738
	12/18/12			896,748	$	2.4	$	2.4	10/31/14	-	896,748
	11/26/12			8,822,887	$	2.4	$	2.4	11/26/17	-	8,822,887
	11/26/12			261,250	$	2.64	$	2.4	11/26/17	-	261,250
	12/18/12			1,494,577	$	2.4	$	4	12/18/17	-	1,494,577
	12/18/12			22,500	$	2.64	$	2.64	12/18/17	-	22,500
	10/29/13			4,455,231	$	0.01	$	0.01	10/29/18	-	4,455,231
	10/29/13			12,868,585	$	2.4	$	2.4	10/31/14	-	12,868,585
	10/29/13			12,868,585	$	4	$	4	10/29/18	-	12,868,585
	10/29/13			65,650	$	2.64	$	2.64	10/29/18	-	65,650
				47,983,752			$	2.68		-	47,983,752

STOCK_OPTION_PLAN

STOCK OPTION PLAN	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
STOCK OPTION PLAN	'
	11. STOCK OPTION PLAN
	The Company’s 2005 Stock Option Plan (the “Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 shares of the Company’s common stock reserved for issuance under the Plan. On April 25, 2011, the Company’s Board of Directors (the “Board”) approved an amendment to the Plan to increase the number of shares of common stock issuable under the Plan to 875,000 shares. On January 14, 2013, the Company’s Board of Directors approved an amendment to the Plan to increase the number of shares of common stock issuable under the Plan to 945,276 shares. On October 7, 2013, the Company’s Board of Directors adopted an amendment to the Company’s 2005 Plan, as amended that increased the number of shares of common stock authorized for issuance thereunder from 945,276 to 11,155,295. Under the Plan, incentives may be granted to officers, employees, directors, consultants, and advisors. Incentives under the Plan may be granted in any one or a combination of the following forms: (a) incentive stock options and non-statutory stock options, (b) stock appreciation rights, (c) stock awards, (d) restricted stock and (e) performance shares.
	The Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than the fair market value of the Company’s common stock on the grant date, and generally vest over a period of three to four years.
	As of December 31, 2013, there are 5,396,822 shares available for future grants and awards under the Plan, which covers stock options, warrants and restricted awards.
	On October 7, 2013, the Board approved a plan to grant 10-year stock options under the 2005 Plan to each of Glenn Mattes, the Company’s President and Chief Executive Officer, Alexander Zukiwski, M.D., the Company’s Chief Medical Officer, and Stefan Proniuk, Ph.D., the Company’s Vice President, Product Development, to purchase 5.5%, 4.5% and 0.65%, respectively, of the number of shares issued by the Company upon the conversion of the Debentures (the “Management Options”). The effective grant date of the Management Options was November 4, 2013, following the complete conversion of the Debentures pursuant to the Conversion Agreement, and the exercise price was fixed at $2.40 per share, reflecting the fair market value of the common stock. The total number of shares subject to the Management Options granted to Mr. Mattes, Dr. Zukiwski and Dr. Proniuk was 386,697, 316,389 and 45,701 shares, respectively. The right to purchase the shares subject to the Management Options will vest in 36 equal monthly installments commencing on the first month anniversary of the date of grant and continuing each month thereafter until fully vested, provided that such vesting shall accelerate upon a “change of control” of the Company, as such term is defined under the 2005 Plan (but excluding any transaction conducted primarily for purposes of raising capital).
	On October 7, 2013, the Board also adopted a standard compensation plan applicable to its non-employee directors (the “Director Compensation Plan”), pursuant to which the Company’s non-employee directors are entitled to cash and equity-based compensation for their services as directors of the Company. Further, on November 4, 2013, and in accordance with the Director Compensation Plan, the Board granted to each non-employee director, 10-year stock options under the 2005 Plan to purchase, at an exercise price of $2.40 per share, a number of shares of Common Stock equal to 0.10% of the then outstanding shares of Common Stock determined on a fully-diluted basis (i.e., assuming the issuance of all shares issuable upon the exercise or conversion of the Company’s outstanding options, warrants or other rights to acquire Common Stock, but excluding all shares reserved for issuance under the 2005 Plan (“Fully-Diluted Basis”)); provided, that the Company’s Chairman of the Board shall instead be granted a stock option to purchase 0.20% of the outstanding shares of Common Stock determined on a Fully-Diluted Basis (collectively the “Director Options”).
	In addition to the Director Options, on November 4, 2013, the Board made one-time grants of 10-year stock options to Arie Belldegrun, M.D., the Company’s Chairman of the Board, and Steven Ruchefsky, to purchase a number of shares of Common Stock equal to 5.0% and 0.2%, respectively, of the shares of Common Stock outstanding on the effective date of such grant, determined on a Fully-Diluted Basis. Such options are subject to the same terms and conditions applicable to the Director Options.
	There were no options granted during the year ended December 31, 2012. During the year ended December 31, 2013, the Company issued 5,038,605 stock options. The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. The following assumptions were used for the year ended December 31, 2013:
			Year Ended
			December 31, 2013
	Expected volatility			89 - 96%	%
	Expected term			4 - 6 years
	Dividend yield			0	%
	Risk-free interest rate			0.77 – 1.35	%
	Stock price		$	2.4
	Forfeiture rate			0	%
	A summary of the status of the options issued under the Plan at December 31, 2013, and information with respect to the changes in options outstanding is as follows:
						Options Outstanding
		Shares				Outstanding			Weighted-			Aggregate
		Available for				Stock			Average			Intrinsic
		Grant				Options			Exercise Price			Value
	Balance at January 1, 2013			112,661			722,358		$	8.88
	Shares authorized for issuance			10,320,276			-
	Options granted under the Plan			-5,038,605			5,038,605		$	2.4
	Options exercised			-			-		$	-
	Options forfeited			2,500			-2,500		$	-
	Balance at December 31, 2013			5,396,832			5,758,463		$	2.66		$	2,237,661
	Exercisable at December 31, 2013						789,905		$	4.28		$	250,238
	The following table summarizes information about stock options outstanding at December 31, 2013:
				Outstanding									Exercisable
	Exercise			Shares			Weighted-			Weighted-			Shares		Weighted-
	Price						Average			Average Exercise					Average Exercise
							Remaining			Price					Price
							Contractual Life
							(Years)
	$	2.4			5,594,152			9.3		$	2.4			625,594	$	2.4
	$	8			117,969			0.08		$	8			117,969	$	8
	$	19.36			37,383			0.03		$	19.36			37,383	$	19.36
	$	24			8,959			0		$	24			8,959	$	24
	Total				5,758,463			9.41		$	2.66			789,905	$	4.28
	Stock-based compensation costs under the Plan for the year ended December 31, 2013 and 2012 and for the cumulative period from August 1, 2005 (inception) through December 31, 2013 are as follows:
									Period from
			Year ended December 31,						August 1, 2005 (inception)
			2013			2012			through December 31, 2013
	Research and development		$	572,741		$	441,983		$	2,559,351
	General and administrative			884,035			280,828			2,568,640
	Total		$	1,456,776		$	722,811		$	5,127,991
	The fair value of options vested under the Plan was approximately $1,507,982 and $863,892 for the years ended December 31, 2013 and 2012, respectively and approximately $4,723,545 for the period from August 1, 2005 (inception) through December 31, 2013.
	At December 31, 2013, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $10,236,586 which is expected to be recognized over a weighted-average vesting period of 2.8 years. This unrecognized estimated employee compensation cost does not include any estimate for forfeitures of performance-based stock options.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is expensed as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.

RELATED_PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
	12. RELATED PARTIES
	On June 1, 2009, the Company entered into a services agreement with Two River Consulting, LLC (“TRC”) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company for a period of one year. David M. Tanen, a director and Secretary of the Company and at the time also its President, Arie S. Belldegrun, M.D., the Chairman of the Board of Directors, and Joshua A. Kazam, a director until September 2010, are each partners of TRC. The terms of the Services Agreement were reviewed and approved by a special committee of the Company’s Board of Directors consisting of independent directors. None of the members of the special committee has any interest in TRC or the services agreement. As compensation for the services contemplated by the services agreement, the Company paid TRC a monthly cash fee of $55,000.   The services agreement with TRC expired on April 1, 2011 and from that point until December 31, 2013, TRC billed the Company for actual hours worked on a monthly basis.  For the years ended December 31, 2013 and 2012, TRC billed the Company $309,330 and $273,171, respectively. For the period from inception to December 31, 2013, TRC has billed the Company a total of $2,052,571. As of January 1, 2014, the Company is no longer receiving services from TRC.
	On occasion, some of the Company’s expenses were paid by TRC. No interest was charged by TRC on any outstanding balance owed by the Company. For the year ended December 31, 2013 and 2012 and for the period from August 1, 2005 (inception) through December 31, 2013 services and reimbursed expenses totaled $347,927, $327,452, and $2,479,144, respectively. As of December 31, 2013, the Company had a payable to TRC of $26,039, which was paid in full during February 2014. As of December 31, 2012, the Company’s payable to TRC was $28,868 and was paid in full during the first two months of 2013.
	The financial condition and results of operations of the Company, as reported, are not necessarily indicative of results that would have been reported had the Company operated completely independently.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	13. INCOME TAXES
	The Company accounts for income taxes using the liability method, which requires the determination of deferred tax assets and liabilities, based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which differences are expected to reverse. The net deferred tax asset is adjusted by a valuation allowance, if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized. The income tax returns of the Company are subject to examination by federal and state taxing authorities. Such examination could result in adjustments to net income or loss, which changes could affect the income tax liabilities of the Company. The Company’s tax returns are open for inspection for all tax years from 2009 to present.
	The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2012, 2011 and the period from August 1, 2005 (inception) through December 31, 2013 and as of December 31, 2013 and 2012, had no amounts accrued for interest and penalties.
	At December 31, 2013, the Company had no Federal income tax expense or benefit but did have Federal tax net operating loss carry-forwards of approximately $56.3 million. The federal net operating loss carry-forwards will begin to expire in 2026, unless previously utilized.
	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets at December 31, 2013 and 2012 are shown below.
		For Years Ended December 31,
		2013			2012
	Non-current deferred tax assets
	Research tax credit	$	2,873,000		$	2,005,000
	Net operating loss carry forwards		22,489,800			15,700,000
	Stock based compensation		437,000			446,000
	Total deferred tax assets		25,799,800			18,151,000
	Non-current deferred tax liability
	Bonus Section 401 Adjustment		-91,000			-
	Depreciation and amortization		-5,000			-10,000
	Total net deferred tax assets		25,703,800			18,141,000
	Valuation allowance		-25,703,800			-18,141,000
	Net deferred tax assets	$	-		$	-
	The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2013 and 2012 the Company recorded valuation allowances of $25.7 million and $18.1 million, respectively, representing a change in the valuation allowance of $7.6 million for the previous fiscal year-ends, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years.
	A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2013 and 2012 are as follows:
		2013				2012
	Federal tax		34	%			34	%
	State tax		5.9	%			5.9	%
	R&D Credit		2.7	%			2.7	%
	Incentive stock options		3.6	%			4.7	%
	Valuation allowance		-46.2	%			-47.3	%
	Net		-				-
	There was no income tax benefit recorded for the years ended December 31, 2013 and 2012.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	14. COMMITMENTS AND CONTINGENCIES
	On August 4, 2011, the Company entered into a lease for office space of approximately 4,168 square feet in Flemington, New Jersey (the “Flemington Lease”). The lease commencement date was November 17, 2011, with lease payments beginning in February 2012.  The lease expiration date is three years from the rent commencement date.  The Company provided a cash security deposit of $10,455, or two months’ base rent.  The Company is also responsible for payment of its share of common area maintenance costs and taxes. The aggregate remaining minimum future payments under the Flemington Lease at December 31, 2013 are approximately $80,550 including common area maintenance charges and taxes. The Flemington Lease contains a three-month free rent period and annual escalations, as such, the Company accounts for rent expense on a straight-line basis. The Company recognized $81,081 and $85,362 in rent expense for the Flemington Lease for the years ended December 31, 2013 and 2012, respectively.
	Future minimum lease payments under operating leases as of December 31, 2013 are as follows:
	2014	$	71,816
	2015		8,734
	Total future minimum lease payments	$	80,550
	On October 29, 2013, in connection with the entry into the 2013 Purchase Agreement, the Company entered into an agreement (the “OPKO Agreement”) with OPKO Health, Inc. (“OPKO”) and Frost Group, LLC (“Frost Group”). Under the terms of the OPKO Agreement, as in inducement to the participation by OPKO and Frost Group (or its affiliates and associates) in the purchase and sale of the Units under the Purchase Agreement, the Company granted OPKO with the following rights, so long as OPKO continues to hold at least 3% of the total number of outstanding shares of the Company’s common stock, determined on a fully-diluted basis (i.e., assuming the issuance of all shares underlying outstanding options, warrants and other rights to acquire common stock): (1) OPKO shall have the right to appoint a non-voting observer to attend all meetings of the Company’s Board of Directors, provided that such appointee enters into a confidentiality agreement with the Company and shall be subject to all applicable Company policies; and (2) OPKO shall have a right of first negotiation that provides it with exclusive rights to negotiate with the company for a 45-day period regarding any potential strategic transactions that the Company’s Board of Directors elects to pursue.
	The Company has entered into various contracts with third parties in connection with the development of the licensed technology described in Note 6.
	The aggregate minimum commitment under these contracts as of December 31, 2013 is approximately $13.0 million, all expected to be due during 2014 and 2016.
	In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of December 31, 2013. The Company does not anticipate recognizing any significant losses relating to these arrangements.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	15. SUBSEQUENT EVENTS
	On January 6, 2014, the Company entered into a Master Development and Commercialization Agreement, effective as of December 23, 2013 (the “Co-Development Agreement”), with Leica Biosystems Newcastle Ltd. (“Leica”), pursuant to which the Company and Leica will collaborate on the development of a companion diagnostic to be used in the clinical development of onapristone, the Company’s lead product candidate being developed for the treatment of breast endometrial and prostate cancers. Under the terms of the Co-Development Agreement, the Company will sponsor and conduct clinical trials for onapristone, and Leica will develop and validate a companion diagnostic to be used to identify patients with activated progestin receptors, who the Company believes are most likely to respond to treatment with onapristone. The Co-Development Agreement contemplates that the parties will enter into separate project agreements from time to time that will specify the details of each party’s responsibilities, including services to be performed, deliverables and compensation, with respect to various phases of the planned development of the companion diagnostic. On March 21, 2014, the Company and Leica entered into the first project agreement under the Co-Development Agreement relating to services to be performed in support of the Company’s ongoing Phase I clinical trials and planned Phase II clinical trial of onapristone.
	On January 8, 2014, the Company and Leica also entered into a License Agreement, effective as of December 23, 2013, pursuant to which each party granted to the other a license to their respective intellectual property to enable each other to carry out their respective obligations in the co-development of the companion diagnostic, including their rights under the Co-Development Agreement. Pursuant to the terms of this license agreement, Leica agreed to pay to the Company certain milestone payments and a single-digit royalty on commercial net sales of the companion diagnostic product to be developed. Further, during the period of the co-development of the companion diagnostic, and for a period of three years following the first commercial sale, Leica agrees not to commercially practice the rights licensed by the Company in connection with, or support the registration or commercialization of, any third party therapeutic agent or product having the same or substantially similar mechanism of action as onapristone; provided, that such period may be extended through the expiration of the last Company patent containing a companion diagnostic claim at the Company’s option by the payment of extension fees specified in the license agreement.
	On February 24, 2014, the Company appointed Lawrence A. Kenyon to serve as its Chief Financial Officer, effective immediately. The terms of Mr. Kenyon’s employment with the Company are set forth in an Employment Agreement (the “Employment Agreement”). The Employment Agreement provides for a term of three years (the “Term”), subject to automatic renewal for successive one-year periods unless either party provides the other party with at least 90 days’ notice of nonrenewal. Pursuant to the Employment Agreement, Mr. Kenyon will receive an initial annualized base salary of $275,000. The Employment Agreement further provides that, subject to the successful achievement of specific performance objectives to be established by Mr. Kenyon and the Chief Executive Officer and approved by the Board, Mr. Kenyon will be eligible to receive an annual performance bonus of up to 30% of his annualized base salary. The Company has also agreed to pay to Mr. Kenyon $100,000 following his relocation to an area near the Company’s headquarters, which amount is subject to repayment as described in the Employment Agreement in the event of Mr. Kenyon’s voluntary termination of his employment (other than for “Good Reason,” as defined in the Employment Agreement) or the Company’s termination of his employment for “Cause” (as defined in the Employment Agreement).
	Pursuant to the Employment Agreement, Mr. Kenyon was granted a 10-year option to purchase a total of 223,445 shares of the Company’s common stock at an exercise price equal to $2.23 per share. The right to purchase 25% of the shares will vest and become exercisable on February 24, 2015, and thereafter the remaining shares will vest and become exercisable in 24 equal monthly installments. Effective as of the close of business on October 31, 2014 and subject to Mr. Kenyon’s continued employment with the Company, Mr. Kenyon will also be granted a ten-year option to purchase an additional number of shares of the Company’s common stock equal to 0.90% of the number of shares of common stock issued by the Company, if any, upon the exercise of the Company’s outstanding 2012 Series B and 2013 Series E Common Stock Purchase Warrants expiring on October 31, 2014. Such option will be granted at an exercise price equal to the fair market value of the Company’s common stock on October 31, 2014, and will vest and become exercisable as to 25% of the shares on October 31, 2015 and as to the remaining shares in 24 equal monthly installments thereafter.
	On February 26, 2014, the Company entered into an Exclusive Patent License Agreement (the “License Agreement”) with the Regents of the University of Minnesota (the “University”), pursuant to which the Company was granted an exclusive, worldwide, royalty-bearing license for the rights to develop and commercialize technology embodied by certain patent applications relating to a gene expression signature derived from archived breast cancer tissue samples. The Company plans to develop and commercialize this technology as a tool to identify progesterone-stimulated pathway activation, which in turn may identify patients who would most likely benefit from treatment with the Company’s lead compound, onapristone, an anti-progestin therapeutic aimed at treatment of men’s and women’s cancers.
	The License Agreement requires the Company to use its commercially reasonable efforts to commercialize the licensed technology as soon as practicable, and includes several performance milestones relating to the development and commercialization of the technology to be achieved by the Company at specified dates beginning in the second quarter of 2014 and continuing during the term of the License Agreement. Under the terms of the License Agreement, the Company is required to make a small one-time cash payment to the University within five business days of the License Agreement and to reimburse the University for past patent expenses it has incurred. The License Agreement also provides that the Company will pay royalties to the University on net sales of “Licensed Products” (as defined in the License Agreement) at a rate in the low-single digits, which royalty obligation terminates on a licensed product-by-licensed product and country-by-country basis upon the first date when there is no longer a valid claim under a licensed patent or patent application covering such licensed product in the country where the licensed product is made or sold.
	The term of the License Agreement continues until the last date on which there is any active licensed patent or pending patent application. The University may terminate the License Agreement earlier upon a breach by the Company of one or more of its obligations that remains uncured for a period specified in the License Agreement. The University may also terminate the License Agreement if the Company voluntarily files for bankruptcy or similar proceeding, or if a petition for an involuntary bankruptcy proceeding is filed and is not released for 60 days. The University may terminate the Licensed Agreement immediately upon notice if the Company commences or maintains a proceeding in which it asserts the licensed patents are invalid or unenforceable. The Company may terminate the Licensed Agreement at any time and for any reason upon 90 days’ written notice.
	The License Agreement further provides that the Company will indemnify and hold the University and its affiliates harmless from any and all suits, actions, claims, liabilities, demands, damages, losses or expenses relating to the Company’s exercise of its rights under the License Agreement, including its right to commercialize the licensed technology. The University is required to indemnify the Company with respect to claims relating to or resulting from its breach of the License Agreement.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates	'
	(a) Use of Estimates
	The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees, directors and consultants, valuation of derivatives and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
Cash and cash equivalents	'
	(b) Cash and Cash Equivalents
	The Company considers all highly liquid investments with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.
Deferred financing fees	'
	(c) Deferred Financing Fees
	Finance costs relating to debt issued are recorded as a deferred charge and amortized to interest expense over the expected term of the debt using the effective interest method.
Prepaid Expenses	'
	(d) Prepaid Expenses
	Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, insurance policies and license fees. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight line method.
Property and Equipment	'
	(e) Property and Equipment
	Property and equipment consist primarily of furnishings, fixtures, leasehold improvements and computer equipment and are recorded at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter.
	Description		Estimated Useful Life
	Office equipment and furniture		5 to 7 years
	Leasehold improvements		3 years
	Computer equipment		3 years
Fair Value of Financial Instruments	'
	(f) Fair Value of Financial Instruments
	The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and derivative liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
Convertible Debentures and Warrant Liability	'
	(g) Convertible Debentures and Warrant Liability
	The Company accounts for the convertible debentures and warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 10) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
Concentration of Credit Risk	'
	(h) Concentration of Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and is insured to the maximum limitations. Balances in these accounts may exceed federally insured limits at times, which expose the Company to institutional risk.
Research and Development	'
	(i) Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Stock-based compensation	'
	(j) Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Share-based compensation is recognized only for those awards that are ultimately expected to vest.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model.  The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.
Loss per Common Share	'
	(k) Loss per Common Share
	Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
	As of December 31, 2013, potentially dilutive securities include:
		December 31, 2013
	Warrants to purchase common stock			34,181,166
	Options to purchase common stock			5,594,151
	Total potentially dilutive securities			39,775,318
	There were no potentially dilutive securities as of December 31, 2012.
	For the year ended December 31, 2013 and 2012, 13,966,897 and 20,726,257 options, warrants and convertible debentures have been excluded from the computation of potentially dilutive securities, respectively, as their exercise prices are greater than the fair market price per common share as of December 31, 2013 and 2012, respectively.
Comprehensive Loss	'
	(l) Comprehensive Loss
	The Company has no components of other comprehensive loss other than its net loss, and accordingly, comprehensive loss is equal to net loss for all periods presented.
Income Taxes	'
	(m) Income Taxes
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the period in which the differences are expected to affect taxable income. The Company provides a valuation allowance when it appears more likely than not that some or all of the net deferred tax assets will not be realized. The Company has not performed an Internal Revenue Section 382 limitation study. Depending on the outcome of such study, the gross amount of net operating losses recognized in future tax periods could be limited.
	A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded.
	The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2013 and 2012 respectively. In addition, the Company had no amounts accrued for interest and penalties as of December 31, 2013 and 2012, respectively.
Recently Issued Accounting Pronouncements	'
	(n) Recently Issued Accounting Pronouncements
	Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Estimated Useful Life Of Property and Equipment	'
	Description	Estimated Useful Life
	Office equipment and furniture	5 to 7 years
	Leasehold improvements	3 years
	Computer equipment	3 years
Potentially Dilutive Securities	'
	As of December 31, 2013, potentially dilutive securities include:
		December 31, 2013
	Warrants to purchase common stock		34,181,166
	Options to purchase common stock		5,594,151
	Total potentially dilutive securities		39,775,318

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment as of December 31, 2013 and 2012 consist of the following:
		2013		2012
	Computer equipment and software	$	17,721	$	17,721
	Office furniture and equipment		52,242		52,242
	Leasehold improvements		8,449		8,449
	Total property and equipment		78,412		78,412
	Accumulated depreciation		-66,692		-53,575
	Total property and equipment, net	$	11,720	$	24,837

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule Of Accrued Liabilities	'
	Accrued liabilities as of December 31, 2013 and 2012 consist of the following:
		2013		2012
	Accrued compensation and related benefits	$	439,156	$	304,772
	Accrued research and development expense		316,099		713,099
	Accrued liquidated damages		-		594,288
	Accrued other expense		170,000		40,000
	Total accrued liabilities	$	925,255	$	1,652,159

CONVERTIBLE_DEBENTURES_Tables

CONVERTIBLE DEBENTURES (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Longterm Notes Payable Current And Noncurrent [Abstract]	'
Schedule of Fair Values on Issuance of Debt Warrant and Debt Conversion Feature	'
	The following table reflects the debt discount for the 2012 Warrants and the embedded conversion feature of the Debentures at their fair values on issuance:
		Issuance
	Debentures, principal			14,857,200
	2012 Warrant liability			-12,430,524
	Debenture conversion feature			-7,548,500
				-5,121,824
Interest Income And Interest Expense	'
	The following table illustrates the components of total interest expense for 2013 and 2012 incurred under the Debentures.
			Year Ended
			December 31,
	Interest Expense		2013		2012
	Note conversion discount		$	14,366,161	$	5,612,863
	Interest expense on 2012 debentures			2,174,244		104,034
	Amortized deferred financing fees			1,709,531		48,844
	Liquidated damages on 2012 debentures			319,221		594,288
	Total Interest Expense		$	18,569,157	$	6,360,029

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	'
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2013:
						Quoted Market
						Prices in Active			Significant Other		Significant
			Fair Value			Markets			Observable Inputs		Unobservable Inputs
			December 31, 2013			(Level 1)			(Level 2)		(Level 3)
	Liabilities
	Warrant liability - 2010 Series B		$	362,452		$	-		$	-	$	362,452
	Warrant liability - 2012 placement agent			362,633			-			-		362,633
	Warrant liability - 2012 Series A&B			16,703,984								16,703,984
	Warrant liability - 2013 placement agent			98,080			-			-		98,080
	Warrant liability - 2013 Series D&E			18,337,732			-			-		18,337,732
	Total		$	35,864,881		$	-		$	-	$	35,864,881
	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2012:
						Quoted Market
						Prices in Active			Significant Other		Significant
			Fair Value			Markets			Observable Inputs		Unobservable Inputs
			December 31, 2012			(Level 1)			(Level 2)		(Level 3)
	Liabilities
	Warrant liability - 2010 Series B		$	898,722		$	-		$	-	$	898,722
	Debenture conversion feature - 2012			7,548,500			-			-		7,548,500
	Warrant liability - 2012 placement agent			542,530			-			-		542,530
	Warrant liability - 2012 Series A&B			12,430,524			-			-		12,430,524
	Total		$	21,420,276		$	-		$	-	$	21,420,276
Summary of Changes in Fair Value of Liabilities	'
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at December 31, 2013:
	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
						2013 Series			2012 Series
						D&E and			A&B and				Debenture
			Total Warrant			Placement			Placement				Conversion
			Liability			Agent			Agent		2010 Series B		Feature
	Balance at January 1, 2012		$	3,705,472							$	3,705,472
	Purchase, sales and settlements:
	Warrants and other derivatives issued			20,521,554						12,973,054				7,548,500
	Total gains or losses:
	Unrealized depreciation			-2,806,750								-2,806,750
	Balance at January 1, 2013		$	21,420,276		$	-		$	12,973,054	$	898,722	$	7,548,500
	Purchase, sales and settlements:
	Warrants and other derivatives issued			15,681,151			15,681,151
	Settlement of derivatives			-5,403,000										-5,403,000
	Total gains or losses:
	Unrealized depreciation			4,166,454			2,754,662			4,093,562		-536,270		-2,145,500
	Balance at December 31, 2013		$	35,864,881		$	18,435,813		$	17,066,616	$	362,452	$	-
	Value per Warrant		$	0.75		$	0.61		$	1.02	$	0.39
Schedule of Derivative Liabilities at Fair Value	'
	Significant assumptions used at December 31, 2013 and 2012 for the warrants and embedded conversion discount derivative liability of the Debentures are as follows:
		December 31, 2013				December 31, 2012
	Volatility			108	%			200	%
	Risk-free interest rate			2.08	%			1.05	%

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	'
	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2013.
	Grant Date	Warrants Issued		Exercise		Weighted		Expiration	Exercised	Warrants
				Price		Average		Date		Outstanding
						Exercise
						Price
	9/3/10		801,885	$	3.55	$	2.82	9/3/15	-	801,885
	9/3/10		132,116	$	8.8	$	8.8	9/3/15	-	132,116
	11/26/12		5,293,738	$	2.4	$	2.4	10/31/14	-	5,293,738
	12/18/12		896,748	$	2.4	$	2.4	10/31/14	-	896,748
	11/26/12		8,822,887	$	2.4	$	2.4	11/26/17	-	8,822,887
	11/26/12		261,250	$	2.64	$	2.4	11/26/17	-	261,250
	12/18/12		1,494,577	$	2.4	$	4	12/18/17	-	1,494,577
	12/18/12		22,500	$	2.64	$	2.64	12/18/17	-	22,500
	10/29/13		4,455,231	$	0.01	$	0.01	10/29/18	-	4,455,231
	10/29/13		12,868,585	$	2.4	$	2.4	10/31/14	-	12,868,585
	10/29/13		12,868,585	$	4	$	4	10/29/18	-	12,868,585
	10/29/13		65,650	$	2.64	$	2.64	10/29/18	-	65,650
			47,983,752			$	2.68		-	47,983,752

STOCK_OPTION_PLAN_Tables

STOCK OPTION PLAN (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model	'
	The following assumptions were used for the year ended December 31, 2013:
			Year Ended
			December 31, 2013
	Expected volatility			89 - 96%	%
	Expected term			4 - 6 years
	Dividend yield			0	%
	Risk-free interest rate			0.77 – 1.35	%
	Stock price		$	2.4
	Forfeiture rate			0	%
Summary of Status of Options Issued And Changes in Options Outstanding	'
	A summary of the status of the options issued under the Plan at December 31, 2013, and information with respect to the changes in options outstanding is as follows:
						Options Outstanding
		Shares				Outstanding			Weighted-			Aggregate
		Available for				Stock			Average			Intrinsic
		Grant				Options			Exercise Price			Value
	Balance at January 1, 2013			112,661			722,358		$	8.88
	Shares authorized for issuance			10,320,276			-
	Options granted under the Plan			-5,038,605			5,038,605		$	2.4
	Options exercised			-			-		$	-
	Options forfeited			2,500			-2,500		$	-
	Balance at December 31, 2013			5,396,832			5,758,463		$	2.66		$	2,237,661
	Exercisable at December 31, 2013						789,905		$	4.28		$	250,238
Summary of Stock Options Outstanding	'
	The following table summarizes information about stock options outstanding at December 31, 2013:
				Outstanding									Exercisable
	Exercise			Shares			Weighted-			Weighted-			Shares		Weighted-
	Price						Average			Average Exercise					Average Exercise
							Remaining			Price					Price
							Contractual Life
							(Years)
	$	2.4			5,594,152			9.3		$	2.4			625,594	$	2.4
	$	8			117,969			0.08		$	8			117,969	$	8
	$	19.36			37,383			0.03		$	19.36			37,383	$	19.36
	$	24			8,959			0		$	24			8,959	$	24
	Total				5,758,463			9.41		$	2.66			789,905	$	4.28
Stock-Based Compensation Costs	'
	Stock-based compensation costs under the Plan for the year ended December 31, 2013 and 2012 and for the cumulative period from August 1, 2005 (inception) through December 31, 2013 are as follows:
									Period from
			Year ended December 31,						August 1, 2005 (inception)
			2013			2012			through December 31, 2013
	Research and development		$	572,741		$	441,983		$	2,559,351
	General and administrative			884,035			280,828			2,568,640
	Total		$	1,456,776		$	722,811		$	5,127,991

INCOME_TAXESTables

INCOME TAXES(Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities	'
	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets at December 31, 2013 and 2012 are shown below.
		For Years Ended December 31,
		2013			2012
	Non-current deferred tax assets
	Research tax credit	$	2,873,000		$	2,005,000
	Net operating loss carry forwards		22,489,800			15,700,000
	Stock based compensation		437,000			446,000
	Total deferred tax assets		25,799,800			18,151,000
	Non-current deferred tax liability
	Bonus Section 401 Adjustment		-91,000			-
	Depreciation and amortization		-5,000			-10,000
	Total net deferred tax assets		25,703,800			18,141,000
	Valuation allowance		-25,703,800			-18,141,000
	Net deferred tax assets	$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation	'
	A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2013 and 2012 are as follows:
		2013				2012
	Federal tax		34	%			34	%
	State tax		5.9	%			5.9	%
	R&D Credit		2.7	%			2.7	%
	Incentive stock options		3.6	%			4.7	%
	Valuation allowance		-46.2	%			-47.3	%
	Net		-				-

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future minimum lease payments under operating leases	'
	Future minimum lease payments under operating leases as of December 31, 2013 are as follows:
	2014	$	71,816
	2015		8,734
	Total future minimum lease payments	$	80,550

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	Dec. 31, 2013
Organization and Nature of Operations [Line Items]	'
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Recovered_Sheet1

Liquidity and Capital Resources - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 31, 2005
Working Capital Detail [Line Items]	'	'	'	'
Cash and cash equivalents	$26,774,203	$10,943,437	$6,678,344	$0

Recovered_Sheet2

The Merger and Basis of Presentation - Additional Information (Detail) (USD $)	1 Months Ended			0 Months Ended	1 Months Ended
	Jun. 03, 2008	Dec. 31, 2013	Dec. 31, 2012	Jun. 02, 2008	Jun. 03, 2008	Jun. 03, 2008
				Old Arno	Old Arno	Laurier International Inc
Shares issuable prior to merger ratio	'	'	'	'	$1.99	'
Shares issued in merger	'	'	'	'	1,611,760	19,291,824
Common stock outstanding prior to merger	'	20,370,331	4,545,618	'	'	1,100,200
Common Stock, Shares, Issued	'	20,370,331	4,545,618	'	'	1,100,200
Ownership interest	'	'	'	'	95.00%	'
Gross proceeds private placement	'	'	'	$17,732,000	'	'
Number of common stock sold to selected accredited investor	'	'	'	3,691,900	'	'
Number of shares issued in business combination	'	'	'	7,360,700	'	'
Notes interest rate	'	'	'	'	6.00%	'
Number of shares issued on conversion of 6% notes	1,962,338	'	'	'	984,246	'
Number of securities called by warrants	196,189	47,983,752	'	'	98,409	'
Per share exercise price of warrant	2.42	'	'	'	4.83	'
Warrant expiration term	'	'	'	'	'5 years	'
Accumulated deficit	$120,538	'	'	'	'	'

Recovered_Sheet3

Summary of Significant Accounting Policies - Additional Information (Detail) (Options, Warrants and Convertible Debentures)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Options, Warrants and Convertible Debentures	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	13,966,897	20,726,257

Straight_Line_Method_over_Rema

Straight - Line Method over Remaining Lease Term or Life of Asset (Detail)	12 Months Ended
	Dec. 31, 2013
Leasehold improvements	'
Property Plant And Equipment Estimated Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years
Computer equipment	'
Property Plant And Equipment Estimated Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years
Maximum | Office equipment and furniture	'
Property Plant And Equipment Estimated Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'7 years
Minimum | Office equipment and furniture	'
Property Plant And Equipment Estimated Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'5 years

Potentially_Dilutive_Securitie

Potentially Dilutive Securities (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'
Total potentially dilutive securities	$39,775,318
Options to purchase common stock	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'
Purchase common stock	5,594,151
Warrants to purchase common stock	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'
Purchase common stock	34,181,166

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation and amortization	$13,117	$13,836	$83,096

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Computer equipment and software	$17,721	$17,721
Office furniture and equipment	52,242	52,242
Leasehold improvements	8,449	8,449
Total property and equipment	78,412	78,412
Accumulated depreciation	-66,692	-53,575
Total property and equipment, net	$11,720	$24,837

Recovered_Sheet4

Intangible Assets and Intellectual Property - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	0 Months Ended		1 Months Ended	12 Months Ended
	Feb. 13, 2012	Jan. 31, 2012	Feb. 13, 2012	Feb. 13, 2012	Oct. 31, 2013	Dec. 31, 2013	Dec. 31, 2008	Dec. 31, 2008	Dec. 31, 2008	Dec. 31, 2013	Jan. 31, 2012
			Onapristone License Agreement	Onapristone License Agreement	Onapristone License Agreement	Onapristone License Agreement	AR-12 and AR-42 License Agreements	AR-12 License Agreement	AR-42 License Agreement	AR-67 License Agreement	AR-67 License Agreement
				Invivis Pharmaceuticals, Inc	Invivis Pharmaceuticals, Inc	Invivis Pharmaceuticals, Inc	Ohio State University Research Foundation	Ohio State University Research Foundation	Ohio State University Research Foundation	University Of Pittsburgh	University Of Pittsburgh
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Cash paid under license agreement	'	'	'	$500,000	$150,000	'	$450,000	'	'	'	'
Aggregate potential milestone payments	'	'	'	15,100,000	'	'	'	6,100,000	5,100,000	'	'
License agreement termination date	'	'	'	13-Feb-32	'	13-Feb-12	'	'	'	'	'
Written notice period for termination of license agreement if breach is not cured	'	'	'90 days	'	'	'	'90 days	'	'	'	'
Prior written notice period for termination of license agreement by the company for any reason	'	'	'	'90 days	'	'	'90 days	'	'	'	'
Potential milestone payments, due after market approval	'	'	'	'	'	'	'	5,000,000	4,000,000	'	'
License agreement expiration date	'	'	'	'	'	'	'20 years	'	'	'	'
Annual license fees	'	'	'	'	'	'	'	'	'	'	235,000
Notice period	'	'60 days	'	'	'	'	'	'	'	'	'
Outstanding license fees	'	'	'	'	'	'	'	'	'	250,000	0
Services agreement expire date	28-Feb-14	'	'	'	'	'	'	'	'	'	'
Services agreement monthly payment	$70,833	'	'	'	'	'	'	'	'	'	'

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued compensation and related benefits	$439,156	$304,772
Accrued research and development expense	316,099	713,099
Accrued liquidated damages	0	594,288
Accrued other expense	170,000	40,000
Total accrued liabilities	$925,255	$1,652,159

Convertible_Debentures_Additio

Convertible Debentures - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Oct. 29, 2013

31-May-13

Mar. 26, 2013

Mar. 27, 2013

Dec. 18, 2012

Dec. 26, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 03, 2008

27-May-13

Dec. 31, 2013

Mar. 27, 2013

Apr. 29, 2013

31-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2010

Nov. 26, 2012

Mar. 25, 2013

Mar. 31, 2013

Oct. 29, 2013

Third And Final Installments

Liquidated Damages

First Installment

Second Installment

CommonStock

CommonStock

Series A Warrant

Series A Warrant

Series B Warrant

Series B Warrant

8% Senior Convertible Debentures

Debentures

Debentures

Debentures

Convertible Long Term Notes Payable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

Aggregate principal amount of debt

'

'

'

'

'

'

'

$14,857,200

'

'

'

'

'

'

'

'

'

'

'

$14,857,200

'

'

$12,230,000

Initial exercise price of warrants

'

'

'

'

'

'

'

'

2.42

'

'

'

'

'

'

4

8

2.4

9.2

'

'

'

'

Number of shares called by warrants

'

'

'

'

'

'

47,983,752

'

196,189

'

'

'

'

'

'

6,190,500

'

6,190,500

'

'

'

'

'

Gross proceeds from issuance on convertible debt and warrant

'

'

'

'

14,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement agent fees and other transaction related expenses

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total value of 2012 Series A & B warrants

'

'

'

'

'

'

'

12,430,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issuable percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

150.00%

'

'

'

'

'

Registrable securities percentage

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

Warrant Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'

'18 months

'

'

'

'

'

Minimum subsequent equity financing

'

'

'

'

'

'

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registration payment arrangement default percentage of liquidated damages

'

'

2.00%

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registration payment arrangement, maximum potential consideration

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Per share conversion price for liquidated damages

'

'

'

'

'

'

'

'

'

'

$2.40

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages (in dollars)

'

288,674

'

'

'

'

913,510

'

'

288,674

'

297,148

327,688

'

305

'

'

'

'

'

'

'

'

Debt instrument, Maturity date, Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'November or December of 2015

'

Debt instrument, Interest rate, Effective percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

Interest expense, debt

'

'

'

'

'

'

5,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of debt discount (Premium)

10,600,000

'

'

'

'

'

14,900,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unpaid accrued interest

'

'

'

'

'

'

$1,187,433

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument convertible conversion price

$2.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued, price per share

'

'

'

'

'

'

$2.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, shares, other

345,606

'

'

'

'

'

494,764

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Issued For Cash

'

'

'

'

'

'

'

'

'

120,280

'

123,809

136,536

380,606

380,606

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

345,606

'

'

'

'

'

'

'

'

'

Number of shares issued on conversion of 2012 debentures

6,530,154

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Discount_for_2012_Warrant

Debt Discount for 2012 Warrants and Embedded Conversion Feature of Debentures (Detail) (USD $)	Dec. 31, 2012
Convertible Long Term Notes Payable [Line Items]	'
Debentures, principal	$14,857,200
2012 Warrant liability	-12,430,524
Debenture conversion feature	-7,548,500
Fair value of debt and warrant liability and debt conversion feature	($5,121,824)

Components_of_Total_Interest_E

Components of Total Interest Expense (Detail) (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Note conversion discount	$14,366,161	$5,612,863	'
Interest expense on 2012 debentures	2,174,244	104,034	'
Amortized deferred financing fees	1,709,531	48,844	'
Liquidated damages on 2012 debentures	319,221	594,288	'
Total Interest Expense	$18,569,157	$6,361,029	$26,190,285

Fair_Value_Hierarchy_for_Liabi

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Measurements, Recurring	'	'
Liabilities	'	'
Warrant liability - 2010 Series B	$362,452	$898,722
Warrant liability - 2012 placement agent	362,633	542,530
Warrant liability - 2012 Series A&B	16,703,984	12,430,524
Debenture conversion feature -2012	'	7,548,500
Warrant liability - 2013 placement agent	98,080	'
Warrant liability - 2013 Series D&E	18,337,732	'
Total	35,864,881	21,420,276
Quoted Market Prices in Active Markets (Level 1)	'	'
Liabilities	'	'
Warrant liability - 2010 Series B	0	0
Warrant liability - 2012 placement agent	0	0
Warrant liability - 2012 Series A&B	'	0
Debenture conversion feature -2012	'	0
Warrant liability - 2013 placement agent	0	'
Warrant liability - 2013 Series D&E	0	'
Total	0	0
Significant Other Observable Inputs (Level 2)	'	'
Liabilities	'	'
Warrant liability - 2010 Series B	0	0
Warrant liability - 2012 placement agent	0	0
Warrant liability - 2012 Series A&B	'	0
Debenture conversion feature -2012	'	0
Warrant liability - 2013 placement agent	0	'
Warrant liability - 2013 Series D&E	0	'
Total	0	0
Significant Unobservable Inputs (Level 3)	'	'
Liabilities	'	'
Warrant liability - 2010 Series B	362,452	898,722
Warrant liability - 2012 placement agent	362,633	542,530
Warrant liability - 2012 Series A&B	16,703,984	12,430,524
Debenture conversion feature -2012	'	7,548,500
Warrant liability - 2013 placement agent	98,080	'
Warrant liability - 2013 Series D&E	18,337,732	'
Total	$35,864,881	$21,420,276

Summary_of_Changes_in_Fair_Val

Summary of Changes in Fair Value of Liabilities (Detail) (USD $)	Jun. 03, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
		Warrant	Warrant	2013 Series D&E and Placement Agent	2013 Series D&E and Placement Agent	2012 Series A&B and Placement Agent	2012 Series A&B and Placement Agent	2010 Series B	2010 Series B	Debenture Conversion Feature [Member]	Debenture Conversion Feature [Member]
Warrant Liability	'	'	'	'	'	'	'	'	'	'	'
Balance	'	$21,420,276	$3,705,472	'	'	$12,973,054	'	$898,722	$3,705,472	$7,548,500	'
Purchases, sales and settlements:	'	'	'	'	'	'	'	'	'	'	'
Warrants and other derivatives issued	'	15,681,151	20,521,554	15,681,151	'	'	12,973,054	'	'	'	7,548,500
Settlment of derivatives	'	-5,403,000	'	'	'	'	'	'	'	-5,403,000	'
Total gains or losses:	'	'	'	'	'	'	'	'	'	'	'
Unrealized depreciation	'	4,166,454	-2,806,750	2,754,662	'	4,093,562	'	-536,270	-2,806,750	-2,145,500	'
Balance	'	$35,864,881	$21,420,276	$18,435,813	'	$17,066,616	$12,973,054	$362,452	$898,722	'	$7,548,500
Value per Warrant	2.42	0.75	'	0.61	'	1.02	'	0.39	'	'	'

Warrants_and_Embedded_Conversi

Warrants and Embedded Conversion Discount Derivative Liability (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Volatility	108.00%	200.00%
Risk-free interest rate	2.08%	1.05%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Oct. 29, 2013

Oct. 30, 2013

31-May-13

Nov. 21, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 03, 2008

Dec. 31, 2010

27-May-13

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Oct. 29, 2013

Dec. 31, 2013

Oct. 31, 2014

Mar. 27, 2013

Apr. 29, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Oct. 29, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Purchase Agreement and 2013 Purchase Agreement

Third And Final Installments

Maxim Group Llc

Maxim Group Llc

Maxim Partners

Class A Warrants

Class B Warrants

Series A Warrant

Series A Warrant

Series B Warrant

Series B Warrant

Series C Warrant

Series D Warrant

Series D Warrant

Series E Warrant

Series E Warrant

First Installment

Second Installment

Securities Purchase and Registration Rights Agreement

Securities Purchase and Registration Rights Agreement

Securities Purchase and Registration Rights Agreement

Securities Purchase and Registration Rights Agreement

Two And One Half Year Class A Warrants

Two And One Half Year Class A Warrants

Five Year Series A Warrants

Five Year Series A Warrants

COMMON STOCK

COMMON STOCK

Series D Warrants and Series E Warrants

Series C Warrants, Series D Warrants and Series E Warrants

Subsequent Event

Class A Warrants

Class B Warrants

Series C Warrant

Series E Warrant

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares authorized before amendment

'

'

'

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares authorized after amendment

'

'

'

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages (in shares)

'

'

'

'

'

'

'

'

120,280

'

'

'

'

'

'

'

'

'

'

'

'

'

'

123,809

136,536

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages (in dollars)

'

'

$288,674

'

$913,510

'

'

'

$288,674

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$297,148

$327,688

'

'

'

'

'

'

'

'

'

'

'

'

Additional shares of common stock issued

'

'

'

'

'

'

'

'

'

283,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,742,215

'

'

Common stock, shares issued

'

'

'

'

20,370,331

4,545,618

'

'

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

'

'

'

'

20,370,331

4,545,618

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares called by warrants

'

'

'

'

47,983,752

'

196,189

'

'

'

'

'

152,704

801,885

6,190,500

'

6,190,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

2.42

3.55

'

2.64

'

'

'

'

4

8

2.4

9.2

'

4

'

'

2.4

'

'

'

'

0.01

2.4

'

'

'

'

'

'

2.4

2.39

Warrant Term

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'18 months

'

'18 months

'

'5 years

'5 years

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

Derivative liabilities

'

'

'

'

35,864,881

21,420,276

'

'

'

500,000

400,000

'

'

'

'

'

'

'

'

'

15,700,000

18,300,000

'

'

'

'

'

'

'

400,000

900,000

16,700,000

12,400,000

'

'

'

'

Placement Fee Paid

'

'

'

'

'

'

'

'

'

1,035,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders equity reverse stock split

'1-for-8 (the Reverse Split).

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends, Common Stock, Cash

'

'

'

'

'

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,413,354

'

Stock Issued During Period, Value, Conversion of Units

'

'

'

'

30,840,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Units Issued Related Cost

'

'

'

'

$760,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale Of Stock Units

'12,826,752 Units

'41,833 Units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12,868,585

'

'

'4,455231

Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights

'

'

'

'

'

'

2.42

3.55

'

2.64

'

'

'

'

4

8

2.4

9.2

'

4

'

'

2.4

'

'

'

'

0.01

2.4

'

'

'

'

'

'

2.4

2.39

Summary_of_All_Outstanding_War

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail)	12 Months Ended
	Dec. 31, 2013	Jun. 03, 2008
Class of Warrant or Right [Line Items]	'	'
Warrants Issued	47,983,752	196,189
Exercise Price	'	2.42
Weighted- Average Exercise Price	2.68	'
Exercised	0	'
Warrants Outstanding	47,983,752	'
Warrant 1	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	3-Sep-10	'
Warrants Issued	801,885	'
Exercise Price	3.55	'
Weighted- Average Exercise Price	2.82	'
Expiration Date	3-Sep-15	'
Exercised	0	'
Warrants Outstanding	801,885	'
Warrant 2	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	3-Sep-10	'
Warrants Issued	132,116	'
Exercise Price	8.8	'
Weighted- Average Exercise Price	8.8	'
Expiration Date	3-Sep-15	'
Exercised	0	'
Warrants Outstanding	132,116	'
Warrant 3	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	26-Nov-12	'
Warrants Issued	5,293,738	'
Exercise Price	2.4	'
Weighted- Average Exercise Price	2.4	'
Expiration Date	31-Oct-14	'
Exercised	0	'
Warrants Outstanding	5,293,738	'
Warrant 4	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	18-Dec-12	'
Warrants Issued	896,748	'
Exercise Price	2.4	'
Weighted- Average Exercise Price	2.4	'
Expiration Date	31-Oct-14	'
Exercised	0	'
Warrants Outstanding	896,748	'
Warrant 5	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	26-Nov-12	'
Warrants Issued	8,822,887	'
Exercise Price	2.4	'
Weighted- Average Exercise Price	2.4	'
Expiration Date	26-Nov-17	'
Exercised	0	'
Warrants Outstanding	8,822,887	'
Warrant 6	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	26-Nov-12	'
Warrants Issued	261,250	'
Exercise Price	2.64	'
Weighted- Average Exercise Price	2.4	'
Expiration Date	26-Nov-17	'
Exercised	0	'
Warrants Outstanding	261,250	'
Warrant 7	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	18-Dec-12	'
Warrants Issued	1,494,577	'
Exercise Price	2.4	'
Weighted- Average Exercise Price	4	'
Expiration Date	18-Dec-17	'
Exercised	0	'
Warrants Outstanding	1,494,577	'
Warrant 8	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	18-Dec-12	'
Warrants Issued	22,500	'
Exercise Price	2.64	'
Weighted- Average Exercise Price	2.64	'
Expiration Date	18-Dec-17	'
Exercised	0	'
Warrants Outstanding	22,500	'
Warrant 9	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	29-Oct-13	'
Warrants Issued	4,455,231	'
Exercise Price	0.01	'
Weighted- Average Exercise Price	0.01	'
Expiration Date	29-Oct-18	'
Exercised	0	'
Warrants Outstanding	4,455,231	'
Warrant 10	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	29-Oct-13	'
Warrants Issued	12,868,585	'
Exercise Price	2.4	'
Weighted- Average Exercise Price	2.4	'
Expiration Date	31-Oct-14	'
Exercised	0	'
Warrants Outstanding	12,868,585	'
Warrant 11	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	29-Oct-13	'
Warrants Issued	12,868,585	'
Exercise Price	4	'
Weighted- Average Exercise Price	4	'
Expiration Date	29-Oct-18	'
Exercised	0	'
Warrants Outstanding	12,868,585	'
Warrant 12	'	'
Class of Warrant or Right [Line Items]	'	'
Grant Date	29-Oct-13	'
Warrants Issued	65,650	'
Exercise Price	2.64	'
Weighted- Average Exercise Price	2.64	'
Expiration Date	29-Oct-18	'
Exercised	0	'
Warrants Outstanding	65,650	'

Stock_Option_Plan_Additional_I

Stock Option Plan - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

101 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

Nov. 04, 2013

Oct. 07, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 04, 2013

Oct. 07, 2013

Nov. 04, 2013

Oct. 07, 2013

Nov. 04, 2013

Oct. 07, 2013

Nov. 04, 2013

Nov. 04, 2013

Nov. 04, 2013

Dec. 31, 2013

Jan. 14, 2013

Apr. 25, 2011

Jun. 03, 2008

Dec. 31, 2013

Oct. 07, 2013

Dec. 31, 2013

Oct. 07, 2013

Nov. 04, 2013

Glenn Mattes

Glenn Mattes

Alexander Zukiwski

Alexander Zukiwski

Stefan Proniuk

Stefan Proniuk

Director Compensation Plan

Arie Belldegrun

Steven Ruchefsky

2005 Plan

2005 Plan

2005 Plan

2005 Plan

2005 Plan

2005 Plan

2005 Plan

2005 Plan

Conversion Debentures Agreement

Maximum

Maximum

Minimum

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock reserved for issuance under 2005 Plan

'

'

10,320,276

'

'

'

'

'

'

'

'

'

'

'

945,276

875,000

373,831

'

11,155,295

'

945,276

'

Term of stock options granted under 2005 Plan (in years)

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'3 years

'

'

Fair value of options vested under 2005 Plan

'

'

$1,507,982

$863,892

'

'

'

'

'

'

'

'

'

$4,723,545

'

'

'

'

'

'

'

'

Total unrecognized estimated compensation cost related to stock options

'

'

$10,236,586

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized estimated compensation cost related to stock options, recognition period

'

'

'2 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares granted

'

'

5,038,605

'

386,697

'

316,389

'

45,701

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant

'

'

5,396,832

112,661

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity Method Investment, Ownership Percentage

'

'

'

'

'

5.50%

'

4.50%

'

0.65%

0.10%

5.00%

0.20%

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

'

'

$2.40

'

'

'

'

'

'

'

$2.40

'

'

'

'

'

'

'

'

'

'

$2.40

Percentage Of Stock Granted To Purchase Common Stock

'

'

'

'

'

'

'

'

'

'

0.20%

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

'36 equal monthly installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions_Used_in_Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Dividend yield	0.00%
Stock price	$2.40
Forfeiture rate	0.00%
Minimum	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected Volatility	89.00%
Expected Term	'4 years
Risk-free interest rate	0.77%
Maximum	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected Volatility	96.00%
Expected Term	'6 years
Risk-free interest rate	1.35%

Summary_of_Status_of_Options_I

Summary of Status of Options Issued and Changes in Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Shares Available for Grant	'
Balance at January 1, 2013	112,661
Shares authorized for issuance	10,320,276
Options granted under the Plan	-5,038,605
Options exercised	0
Options forfeited	2,500
Balance at December 31, 2013	5,396,832
Outstanding Stock Options	'
Balance at January 1, 2013	722,358
Shares authorized for issuance	0
Options granted under the Plan	5,038,605
Options exercised	0
Options forfeited	-2,500
Balance at December 31,2013	5,758,463
Exercisable at December 31, 2013	789,905
Options Outstanding Weighted-Average Exercise Price	'
Balance at January 1, 2013	$8.88
Options granted under the Plan	$2.40
Options exercised	$0
Options forfeited	$0
Balance at December 31, 2013	$2.66
Exercisable at December 31, 2013	$4.28
Options Outstanding Aggregate Intrinsic Value	'
Balance at December 31, 2013	$2,237,661
Exercisable at December 31, 2013	$250,238

Summary_of_Information_about_S

Summary of Information about Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Shares	5,758,463	722,358
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'9 years 4 months 28 days	'
Options Outstanding, Weighted-Average Exercise Price	$2.66	$8.88
Options Exercisable, Total Shares	789,905	'
Options Exercisable, Weighted- Average Exercise Price	$4.28	'
Exercise Price 1	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Price	$2.40	'
Options Outstanding, Shares	5,594,152	'
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'9 years 3 months 18 days	'
Options Outstanding, Weighted-Average Exercise Price	$2.40	'
Options Exercisable, Total Shares	625,594	'
Options Exercisable, Weighted- Average Exercise Price	$2.40	'
Exercise Price 2	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Price	$8	'
Options Outstanding, Shares	117,969	'
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'29 days	'
Options Outstanding, Weighted-Average Exercise Price	$8	'
Options Exercisable, Total Shares	117,969	'
Options Exercisable, Weighted- Average Exercise Price	$8	'
Exercise Price 3	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Price	$19.36	'
Options Outstanding, Shares	37,383	'
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'11 days	'
Options Outstanding, Weighted-Average Exercise Price	$19.36	'
Options Exercisable, Total Shares	37,383	'
Options Exercisable, Weighted- Average Exercise Price	$19.36	'
Exercise Price 4	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Price	$24	'
Options Outstanding, Shares	8,959	'
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'0 years	'
Options Outstanding, Weighted-Average Exercise Price	$24	'
Options Exercisable, Total Shares	8,959	'
Options Exercisable, Weighted- Average Exercise Price	$24	'

StockBased_Compensation_Costs_

Stock-Based Compensation Costs (Detail) (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	$1,456,776	$722,811	$5,127,991
Research and development	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	572,741	441,983	2,559,351
General and administrative	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	$884,035	$280,828	$2,568,640

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'	'
Amount payable to TRC	$26,039	$28,268	$26,039
Total cash services and reimbursed expenses	347,927	327,452	2,479,144
Two River Consulting Llc	'	'	'
Related Party Transaction [Line Items]	'	'	'
Amount payable to TRC	55,000	'	55,000
Related party transactions total billed amount for services rendered	309,330	273,171	'
Related Party Transactions Billed Amount For Services Rendered Per Month	$2,052,571	$28,868	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Deferred Tax Assets, Valuation Allowance	$25,703,800	$18,141,000
Valuation Allowance, Deferred Tax Asset, Change in Amount	'	7,600,000
Operating Loss Carry forward Expiration Date	'2026	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$56,300,000	'

Schedule_of_Deferred_Tax_Asset

Schedule of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Non-current deferred tax assets	'	'
Research tax credit	$2,873,000	$2,005,000
Net operating loss carry forwards	22,489,800	15,700,000
Stock based compensation	437,000	446,000
Total deferred tax assets	25,799,800	18,151,000
Non-current deferred tax liability	'	'
Bonus Section 401 Adjustment	-91,000	0
Depreciation and amortization	-5,000	-10,000
Total net deferred tax assets	25,703,800	18,141,000
Valuation allowance	-25,703,800	-18,141,000
Net deferred tax assets	$0	$0

Reconciliation_of_Statutory_Ta

Reconciliation of Statutory Tax Rates and Effective Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]	'	'
Federal tax, Rate	34.00%	34.00%
State tax, Rate	5.90%	5.90%
R&D Credit, Rate	2.70%	2.70%
Incentive stock options, Rate	3.60%	4.70%
Valuation allowance, Rate	-46.20%	-47.30%
Net, Rate	0.00%	0.00%

Recovered_Sheet5

Commitments and Contingencies - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Aug. 04, 2011
			Flemington Lease	Flemington Lease	Flemington Lease sqft
					acre
Commitments And Contingencies Disclosure [Line Items]	'	'	'	'	'
Deposits Assets, Noncurrent	$10,455	$10,455	'	'	'
Area of Land	'	'	'	'	4,168
Capital Leases, Future Minimum Payments, Net Minimum Payments, Total	'	'	80,550	'	'
Operating Leases, Rent Expense	'	'	81,081	85,362	'
Purchase Commitment, Remaining Minimum Amount Committed	'	$13,000,000	'	'	'

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments Under Operating Leases (Detail) (USD $)	Dec. 31, 2013
Future Minimum Rental Payment For Operating Leases	'
2014	$71,816
2015	8,734
Total future minimum lease payments	$80,550

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2013	Feb. 24, 2014	Feb. 24, 2014
	Lawrence A. Kenyon	Subsequent Event	Subsequent Event
		Board of Directors Chairman	Lawrence A. Kenyon
Subsequent Events [Line Items]	'	'	'
Common Stock Exercise Price	'	$2.23	'
Purchase of shares authorized	'	223,445	'
Granted contractual term	'	'10	'
Accrued salaries current	'	'	$275,000
Percentage of annual performance bonus	'	'	30.00%
Other employee related liabilities	'	'	$100,000
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage	'	'	25.00%
Share-based compensation arrangement by share-based payment award, equity instruments other than options, exercisable date	24-Feb-15	'	'
Share-based compensation arrangement by share-based payment award, award vesting rights	'option will be granted at an exercise price equal to the fair market value of the Company’s common stock on October 31, 2014, and will vest and become exercisable as to 25% of the shares on October 31, 2015 and as to the remaining shares in 24 equal monthly installments thereafter.	'	'